var title_f23_45_24272="Upright BOB technique for shoulder reduction";
var content_f23_45_24272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/EM/68113/BOB.mp4?title=Upright+BOB+technique+for+shoulder+reduction\" style=\"width:448px;height:352px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Upright best-of-both (BOB) shoulder reduction technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Simon and Sherman, Emergency Orthopedics, 6th edition. DVD &copy; Scott Sherman. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24272=[""].join("\n");
var outline_f23_45_24272=null;
var title_f23_45_24273="Diagram showing AV graft for hemodialysis";
var content_f23_45_24273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F59794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F59794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram showing AV graft for hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This drawing shows an AV graft in a person's arm. A graft is under the skin. A doctor makes a graft by doing surgery. He or she uses a flexible rubber tube to connect an artery to a vein. During hemodialysis, 2 needles are put into the graft to remove and return blood to the body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24273=[""].join("\n");
var outline_f23_45_24273=null;
var title_f23_45_24274="True AP x-ray of the thumb (Roberts view)";
var content_f23_45_24274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69169&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    True AP x-ray of the thumb (Roberts view)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 568px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Roberts view or \"True\" anterior-posterior (AP) radiograph of the thumb allows better visualization of the trapezium without significant overlap of other bones. A close-up of the trapezium (inset) shows a fracture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24274=[""].join("\n");
var outline_f23_45_24274=null;
var title_f23_45_24275="Osteoporosis PI";
var content_f23_45_24275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 526px\">",
"   <div class=\"ttl\">",
"    Bones affected by osteoporosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 506px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The bones in this picture are called \"vertebrae.\" The one on the left is healthy. Its spongy center has lots of hard fibers that are connected to each other. The one on the right has osteoporosis. Its spongy center has fewer, thinner fibers that are no longer connected. The surrounding shell of compact bone is thinner. This makes the vertebra weak. That's why it got crushed under the weight it was holding.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24275=[""].join("\n");
var outline_f23_45_24275=null;
var title_f23_45_24276="Recovery of renal function after relief of urinary tract obstruction";
var content_f23_45_24276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Recovery of renal function after relief of urinary tract obstruction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24276/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/45/24276/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is clear that complete or prolonged partial urinary tract obstruction (UTO) can lead to tubular atrophy and eventually irreversible renal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The renal prognosis after relief of urinary tract obstruction is dependent upon the severity and duration of the obstruction. With total ureteral obstruction, for example, there is evidence that relatively complete recovery of glomerular filtration rate (GFR) can be achieved within one week, while little or no recovery occurs after 12 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, measurement of the GFR probably overestimates the true degree of recovery. In a rat model in which complete unilateral ureteral obstruction was induced for only 24 hours, approximately 15 percent of nephrons were nonfunctional as late as 60 days after release, a presumed reflection of irreversible injury [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite this nephron loss, the GFR returned to normal because of hypertrophy and hyperfiltration in the remaining functional nephrons. It is likely that a similar process of compensatory hypertrophy occurs in human obstruction, since it has been demonstrated in other diseases such as lupus nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course of partial obstruction is less predictable. It clearly depends on the severity and duration of the obstruction, as well as other potential complicating factors, such as hypertension, infection, or preexisting renal disease. It is not uncommon, for example, to see an adult who is noted to have moderate or even massive hydronephrosis due to previously unsuspected ureteropelvic junctional obstruction. In this setting, pain may occur only during periods of high fluid intake when the urine flow rate exceeds the rate at which urine can flow through the obstructed area. Correction of the obstruction may not be necessary if the patient is largely asymptomatic, the plasma creatinine concentration is normal, and there seems to be little or no parenchymal atrophy on renal ultrasonography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FUNCTIONAL RECOVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the unreliability of clinical indices, radionuclide scanning and renal ultrasonography have been used in an attempt to predict the likelihood of functional recovery. Adverse prognostic findings thought to be indicative of severe and usually irreversible disease include total nonvisualization on renal scan and marked cortical thinning on ultrasonography. However, these findings may not be useful in the individual patient, since their presence does not preclude substantial return or even near normalization of the GFR following release of the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the functional recovery will usually be seen in the first 7 to 10 days after relief of the obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. However, some patients with severe renal failure may, after the obstruction is relieved, require dialysis for a period of weeks until sufficient improvement occurs to allow dialysis to be discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/7\">",
"     7",
"    </a>",
"    ]. Only partial recovery is seen in this setting with the plasma creatinine concentration generally stabilizing at a value above 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (264",
"    <span class=\"nowrap\">",
"     &micro;mol/L).",
"    </span>",
"   </p>",
"   <p>",
"    In addition to the persistent reduction in GFR, tubular function may also be impaired by chronic obstruction. This may be manifested by polyuria due to decreased concentrating ability (because of decreased expression of water channels), mild sodium wasting the severity of which is usually limited by the low filtration rate, and by distal renal tubular acidosis with hyperkalemia due to diminished distal hydrogen and potassium secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=see_link\">",
"     \"Urine output in urinary tract obstruction and postobstructive diuresis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=see_link\">",
"     \"Pathophysiology of renal tubular acidosis and the effect on potassium balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mechanism by which UTO leads to irreversible renal injury and atrophy is incompletely understood. Following the onset of obstruction, there is an initial increase in pressure proximal to the obstruction due to continued glomerular filtration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8\">",
"     8",
"    </a>",
"    ]; this rise in pressure is eventually responsible for the dilatation of the collecting systems that can be detected by renal ultrasonography or CT scanning. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=see_link\">",
"     \"Diagnosis of urinary tract obstruction and hydronephrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The elevation in pressure is also transmitted back to the proximal tubule, thereby lowering the GFR by counteracting the high intraglomerular pressure that normally drives glomerular filtration. However, the rise in intratubular pressure induces secondary renal vasoconstriction and an often marked reduction in glomerular blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. This response is regulated locally by individual obstructed nephrons and is mediated in part by the release of angiotensin II and thromboxanes [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. It can be viewed as an appropriate physiologic adaptation, since the increase in local glomerular resistance shunts blood flow away from obstructed nonfunctioning nephrons [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect is that the chronic reduction in GFR is due primarily to the decrease in renal perfusion; as a result, the elevated intratubular pressures slowly fall toward normal [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8,14\">",
"     8,14",
"    </a>",
"    ]. Studies in which renal pelvic pressures were monitored suggest that a similar process occurs in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the tubular injury that occurs with UTO may be mediated initially by the increase in intratubular pressure and later by atrophy induced by ischemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. The importance of increased intrarenal pressure is supported by findings in obstructed animals that the associated tubular dysfunction can be ameliorated, but not prevented, by renal decapsulation which limits the rise in pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The injury that is independent of pressure may be due both to ischemia and to the influx of inflammatory cells. The obstructed kidney appears to release substances that are chemotactic for monocytes and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/8,18,19\">",
"     8,18,19",
"    </a>",
"    ]. These infiltrating cells can then release transforming growth factor-beta (TGF-beta) and other cytokines, proteases and oxygen free radicals that may contribute to tubular injury and fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/18\">",
"     18",
"    </a>",
"    ]. Further support for a role for TGF-beta is provided by experimental data suggesting that administration of a TGF-beta inhibitor suppresses fibrosis in obstructive uropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The combination of tubular atrophy and inflammatory cell injury can, over a period of time, lead to irreversible injury and interstitial fibrosis that limits the restoration of renal function when the obstruction is relieved [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24276/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete or partial urinary tract obstruction may lead to irreversible renal injury. The renal prognosis is dependent upon the severity and duration of the obstruction, as well as other potential complicating factors, such as hypertension, infection, or preexisting renal disease. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measurement of the glomerular filtrate rate (GFR) following relief of obstruction may overestimate the degree of recovery in the nephron population. Despite nephron loss, the GFR may return to normal because of hypertrophy and hyperfiltration in the remaining functional nephrons. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most functional recovery is usually seen in the first 7 to 10 days following relief of obstruction. Some patients may require dialysis for a period of weeks until partial recovery occurs. Irreversible disease is suggested by nonvisualization on renal scan and marked cortical thinning on ultrasonography; however, these findings do not preclude at least partial return of the GFR following release of the obstruction. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functional recovery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tubular function may be impaired by chronic obstruction resulting in polyuria, mild sodium wasting or inability to achieve appropriate sodium conservation, and distal renal tubular acidosis with hyperkalemia due to diminished distal hydrogen and potassium secretion. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Functional recovery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism by which obstruction leads to irreversible renal injury is incompletely understood. An increase in pressure proximal to the obstruction lowers the GFR by counteracting the high intraglomerular pressure that normally drives glomerular filtration. The rise in intratubular pressure also induces renal vasoconstriction and a reduction in glomerular blood flow. The chronic reduction in GFR is due primarily to the decrease in renal perfusion, which tends to decrease the elevated intraluminal pressure over time. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The tubular injury that occurs with obstruction may be mediated initially by the increase in intratubular pressure and later by atrophy induced by ischemia or disuse. Ischemia and an influx of inflammatory cells that release cytokines, proteases and oxygen free radicals likely contribute to irreversible tubular injury and fibrosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/1\">",
"      Sacks SH, Aparicio SA, Bevan A, et al. Late renal failure due to prostatic outflow obstruction: a preventable disease. BMJ 1989; 298:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/2\">",
"      Better OS, Arieff AI, Massry SG, et al. Studies on renal function after relief of complete unilateral ureteral obstruction of three months' duration in man. Am J Med 1973; 54:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/3\">",
"      Bander SJ, Buerkert JE, Martin D, Klahr S. Long-term effects of 24-hr unilateral ureteral obstruction on renal function in the rat. Kidney Int 1985; 28:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/4\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/5\">",
"      McAfee JG, Singh A, O'Callaghan JP. Nuclear imaging supplementary to urography in obstructive uropathy. Radiology 1980; 137:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/6\">",
"      Green J, Vardy Y, Munichor M, Better OS. Extreme unilateral hydronephrosis with normal glomerular filtration rate: physiological studies in a case of obstructive uropathy. J Urol 1986; 136:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/7\">",
"      Cohen EP, Sobrero M, Roxe DM, Levin ML. Reversibility of long-standing urinary tract obstruction requiring long-term dialysis. Arch Intern Med 1992; 152:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/8\">",
"      Klahr S. New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy. Am J Kidney Dis 1991; 18:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/9\">",
"      Hwang SJ, Haas M, Harris HW Jr, et al. Transport defects of rabbit medullary thick ascending limb cells in obstructive nephropathy. J Clin Invest 1993; 91:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/10\">",
"      Hwang SJ, Harris HW Jr, Otuechere G, et al. Transport defects of rabbit inner medullary collecting duct cells in obstructive nephropathy. Am J Physiol 1993; 264:F808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/11\">",
"      Murer L, Addabbo F, Carmosino M, et al. Selective decrease in urinary aquaporin 2 and increase in prostaglandin E2 excretion is associated with postobstructive polyuria in human congenital hydronephrosis. J Am Soc Nephrol 2004; 15:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/12\">",
"      Tanner GA, Knopp LC. Glomerular blood flow after single nephron obstruction in the rat kidney. Am J Physiol 1986; 250:F77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/13\">",
"      Klotman PE, Smith SR, Volpp BD, et al. Thromboxane synthetase inhibition improves function of hydronephrotic rat kidneys. Am J Physiol 1986; 250:F282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/14\">",
"      Gaudio KM, Siegel NJ, Hayslett JP, Kashgarian M. Renal perfusion and intratubular pressure during ureteral occlusion in the rat. Am J Physiol 1980; 238:F205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/15\">",
"      Michaelson G. Percutaneous puncture of the renal pelvis, intrapelvic pressure and the concentrating capacity of the kidney in hydronephrosis. Acta Med Scand Suppl 1974; 559:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/16\">",
"      Tanner GA, Evan AP. Glomerular and proximal tubular morphology after single nephron obstruction. Kidney Int 1989; 36:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/17\">",
"      Muto S, Asano Y. Electrical properties of the rabbit cortical collecting duct from obstructed kidneys after unilateral ureteral obstruction. Effects of renal decapsulation. J Clin Invest 1994; 94:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/18\">",
"      Schreiner GF, Kohan DE. Regulation of renal transport processes and hemodynamics by macrophages and lymphocytes. Am J Physiol 1990; 258:F761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/19\">",
"      Ophascharoensuk V, Giachelli CM, Gordon K, et al. Obstructive uropathy in the mouse: role of osteopontin in interstitial fibrosis and apoptosis. Kidney Int 1999; 56:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/20\">",
"      Moon JA, Kim HT, Cho IS, et al. IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int 2006; 70:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24276/abstract/21\">",
"      Shin GT, Kim WH, Yim H, et al. Effects of suppressing intrarenal angiotensinogen on renal transforming growth factor-beta1 expression in acute ureteral obstruction. Kidney Int 2005; 67:897.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7185 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24276=[""].join("\n");
var outline_f23_45_24276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FUNCTIONAL RECOVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25190?source=related_link\">",
"      Diagnosis of urinary tract obstruction and hydronephrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/13/19672?source=related_link\">",
"      Pathophysiology of renal tubular acidosis and the effect on potassium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12050?source=related_link\">",
"      Urine output in urinary tract obstruction and postobstructive diuresis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24277="Gadopentetate dimeglumine: Drug information";
var content_f23_45_24277=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadopentetate dimeglumine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/17/43283?source=see_link\">",
"    see \"Gadopentetate dimeglumine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Magnevist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F4663222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Magnevist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, High Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MRI: I.V.: 0.1 mmol/kg  (0.2 mL/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Dosing for patients &gt;130 kg (286 pounds) has not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F175105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     MRI: I.V.: Children &ge;2 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F3062827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has been shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F175101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Magnevist&reg;: 469.01 mg/mL (5 mL, 10 mL, 15 mL, 20 mL, 50 mL, 100 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should be administered at a rate not to exceed 10 mL per 15 seconds. Complete imaging procedure within 1 hour of injection. Following administration, flush line with NS 5 mL.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175085\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance imaging (MRI) to visualize CNS lesions with abnormal vascularity in the brain, spine and associated tissues, extracranial/extraspinal lesions with abnormal vascularity in the head and neck, and body lesions with abnormal vascularity (excluding the heart)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12931741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance angiography (MRA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5%), dizziness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site coldness/localized coldness (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reactions, anaphylactic shock, angina, angioedema, arrhythmia, bradycardia, cardiac arrest, coma, compartment syndrome, DVT, diplopia, edema, epidermal necrolysis, erythema multiforme, hearing impaired, hypersensitivity reactions (delayed), injection site reactions (burning, localized warmth, fasciitis, pain), laryngeal edema, laryngospasm, MI, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), nystagmus, parosmia, phlebitis, pulmonary edema, renal failure, renal impairment, respiratory arrest, respiratory distress, seizures, shock, syncope, tachycardia, thrombophlebitis, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chronic severe kidney disease (GFR &lt;30 mL/min/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ); acute kidney injury; hypersensitivity to any gadolinium-based contrast agent",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within several hours of administration). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis:",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. Use is contraindicated in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; contraindicated in patients with acute kidney injury or chronic, severe renal impairment (GFR &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Sickling, possibly leading to vaso-occlusion, has been reported (rare, case reports) with use of hyperosmolar contrast solutions; believed to result from red blood cell dehydration. Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Injection site reactions: Site of contrast injection or limb may develop thrombosis with fasciitis, skin and soft tissue necrosis, and/or compartment syndrome requiring surgical intervention (rare); assess line patency prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Repeat doses: Safety of repeat doses has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Scan interpretation: Use caution when interpreting a contrast-enhanced scan in the absence of a companion unenhanced noncontrast MRI.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6220551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Gadopentetate dimeglumine crosses the placenta in humans (Marcos, 1997). Gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F175091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Following administration of gadopentetate dimeglumine 0.1 mmol/kg, &lt;0.04% gadolinium was excreted in breast milk within 24 hours. In an average 70 kg woman, this would be equivalent to &lt;3 micromol of gadolinium transferred to a breast-feeding infant. The duration of excretion into breast milk and the possible effects to the infant are not known. Some sources state breast-feeding may be continued. Contrast media may temporarily alter the taste of breast milk (Kubik-Huch, 2000; Tremblay, 2012; Webb, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Magnevist Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     469.01 mg/mL (20 mL): $127.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F175082\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Patient and injection site should be monitored for signs of hypersensitivity for several hours following injection; renal function (prior to administration); short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Gadomin (PH);",
"     </li>",
"     <li>",
"      Magnegita (SG);",
"     </li>",
"     <li>",
"      Magnetol (IL);",
"     </li>",
"     <li>",
"      Magnevist (AT, AU, BE, BG, CH, CO, CR, CZ, DE, DK, DO, EE, FI, FR, GR, GT, HN, IN, IT, NI, NL, NO, NZ, PA, PE, PT, RU, SE, SV, UY, ZA);",
"     </li>",
"     <li>",
"      Magnevistan (BR, CN, VE);",
"     </li>",
"     <li>",
"      Megaray (KP);",
"     </li>",
"     <li>",
"      Viewgam (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exposure to an external magnetic field induces a large local magnetic field in gadopentetate exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 266 &plusmn; 43 mL/kg; does not cross intact blood-brain barrier; distribution half-life: 0.2 &plusmn; 0.13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.6 &plusmn; 0.13 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~91% as gadopentetate)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Nephrogenic Fibrosing Dermopathy Associated with Exposure to Gadolinium-Containing Contrast Agents: St. Louis, Missouri,&rdquo;",
"      <i>",
"       MMWR Weekly Rep",
"      </i>",
"      , 2007, 56(07):137-141.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013, 37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Grobner T, &ldquo;Gadolinium - A Specific Trigger for the Development of Nephrogenic Fibrosing Dermopathy and Nephrogenic Systemic Fibrosis,&rdquo;",
"      <i>",
"       Nephrol Dial Transplant",
"      </i>",
"      , 2006, 21(4):1104-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/16431890/pubmed\" id=\"16431890\" target=\"_blank\">",
"        16431890",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kubik-Huch RA, Gottstein-Aalame NM, Frenzel T, et al, \"Gadopentetate Dimeglumine Excretion Into Human Breast Milk During Lactation,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2000, 216(2):555-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/10924585/pubmed\" id=\"10924585\" target=\"_blank\">",
"        10924585",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marcos HB, Semelka RC, and Worawattanakul S, \"Normal Placenta: Gadolinium-Enhanced Dynamic MR Imaging,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 1997, 205(2):493-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/9356634/pubmed\" id=\"9356634\" target=\"_blank\">",
"        9356634",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      , 2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wanko SO, Telen MJ, &ldquo;Transfusion Management in Sickle Cell Disease,&rdquo;",
"      <i>",
"       Hematol Oncol Clin N Am",
"      </i>",
"      , 2005, 19(5):803-26.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK, \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005, 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24277/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Widmark JM, &ldquo;Imaging-related Medications: A Class Overview,&rdquo;",
"      <i>",
"       Proc(Bayl Univ Med Cent)",
"      </i>",
"      , 2007, 20(4):408-17.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8881 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24277=[""].join("\n");
var outline_f23_45_24277=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708885\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175098\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4663222\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175111\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175099\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175105\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3062827\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175100\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175101\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175084\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175074\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175086\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175085\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931741\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174542\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175109\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175089\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175076\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299379\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6220551\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175081\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175090\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175103\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175091\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323164\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175082\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038645\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175075\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175088\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8881\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8881|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/17/43283?source=related_link\">",
"      Gadopentetate dimeglumine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24278="Tumor node metastasis (TNM) staging classification for breast cancer";
var content_f23_45_24278=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Tumor node metastasis (TNM) staging classification for breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24278/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/45/24278/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastasis (TNM) staging system for breast cancer is an internationally accepted system used to determine the disease stage. This disease stage is a measure of the extent of disease, which is used to guide management and determine prognosis.",
"   </p>",
"   <p>",
"    The seventh edition of the TNM staging system, and the evidence supporting it, are described here (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ). The sixth edition of the TNM staging system is included for comparison (",
"    <a class=\"graphic graphic_table graphicRef73355 \" href=\"UTD.htm?15/58/16303\">",
"     table 2",
"    </a>",
"    ). The initial evaluation, clinical manifestations, diagnosis, treatment, and prognosis of breast cancer are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TNM STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor node metastasis (TNM) staging system for breast cancer is based upon a retrospective analysis of survival in diverse samples of patients representing all stages of disease. It reflects the clinical evaluation methods and treatments that are applied to the particular study population.",
"   </p>",
"   <p>",
"    The TNM staging system is used to facilitate discussions about treatment and prognosis between collaborating providers, as well as between providers and patients. An individual patient's clinical course and outcome cannot be predicted with certainty. However, available survival data can help direct treatment decisions and provide an estimate of the likely prognosis. The TNM staging system correlates important tumor characteristics with survival data to help estimate and follow outcomes.",
"   </p>",
"   <p>",
"    Periodic revisions are necessary because advanced imaging techniques and treatments evolve and impact survival. The seventh edition of the TNM staging system is the most recent version (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24278/abstract/1\">",
"     1",
"    </a>",
"    ]. The sixth edition of the TNM staging system is shown in the table (",
"    <a class=\"graphic graphic_table graphicRef73355 \" href=\"UTD.htm?15/58/16303\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24278/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL VERSUS PATHOLOGIC STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each characteristic of a tumor (size, nodal involvement, metastases) can be evaluated and reported either clinically or pathologically. Pathologic staging is generally considered to be more accurate than clinical staging. However, there are instances in which the clinical staging is useful for making initial treatment recommendations and determining eligibility for clinical trials. Subsequent pathology may alter the clinical TNM classification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     REVISIONS IN BREAST CANCER STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observed survival rates for 211,645 breast cancer cases diagnosed in years 2001-2002 and entered into the National Cancer Data Base (Commission on Cancer of the American College of Surgeons and the American Cancer Society) were used to reevaluate the prognostic value of the TNM descriptors.",
"   </p>",
"   <p>",
"    Modest adjustments have been made to the T, N and M categories for the seventh edition of the staging system for breast cancer, in an effort to reflect new technologies and new clinical outcome data since the sixth edition (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ). The most important changes in the new staging system include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Changes in Tumor (T) classification",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The microscopic measurement is considered most accurate for small invasive cancers that can be entirely submitted in one paraffin block.",
"     </li>",
"     <li>",
"      The gross measurement is considered most accurate for larger invasive cancers that are submitted in multiple paraffin blocks.",
"     </li>",
"     <li>",
"      For patients being treated with neoadjuvant treatment, the most accurate clinical measurement should be used to determine the clinical T at presentation. Posttreatment T size should be estimated based on the best combination of gross and microscopic histological findings.",
"     </li>",
"     <li>",
"      Paget disease associated with an underlying cancer should be classified according to the underlying cancer (Tis, T1 etc.)",
"     </li>",
"     <li>",
"      Paget disease that is not associated with an underlying cancer should be classified as Tis (Paget).",
"     </li>",
"     <li>",
"      The size of noninvasive cancers, ductal carcinoma in situ (DCIS) and lobular carcinoma in situ (LCIS), should be estimated, as this may influence therapeutic decision making.",
"     </li>",
"     <li>",
"      Multiple simultaneous ipsilateral carcinomas can occur in the same quadrant or separate quadrants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Changes in Nodes (N) classification",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More stringent classification of isolated tumor cell clusters and single cells is now required. Small clusters of cells not greater than 0.2 mm, or nonconfluent or nearly confluent clusters of cells not exceeding 200 cells in a single histologic lymph node cross section are classified as isolated tumor cells.",
"     </li>",
"     <li>",
"      Use of the (sn) modifier has been clarified and restricted. When six or more sentinel nodes are identified on gross examination of pathology specimens, the (sn) modifier is now omitted.",
"     </li>",
"     <li>",
"      Stage I breast tumors have been subdivided into stage IA and stage IB; stage IB includes small tumors (T1) with exclusively micrometastases in lymph nodes (N1mi).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Changes in Metastases (M) classification",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A new M0(i+) category has been created, defined by the presence of either disseminated tumor cells detectable in bone marrow or circulating tumor cells or found incidentally in other tissues if not exceeding 0.2 mm. However, this category does not change the stage grouping. Assuming patients do not have clinically or radiographically detectable metastases, staging for patients with M0(i+) is done according to T and N.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Changes in postneoadjuvant therapy (yc or ypTNM) classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;This nomenclature is used for cases where systemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy are given before surgery (neoadjuvant) or where no surgery is performed. These patients will have the extent of disease assessed at the conclusion of the therapy by clinical or pathologic means to provide information about the extent of response to help direct the extent of any subsequent treatment. T and N are classified using the same categories as for clinical or pathologic staging for the disease, and the findings are recorded with the appropriate prefix (ycT, ycN, ypT, ypN). The yc prefix is used for the clinical stage after therapy, and the yp prefix is used for the pathologic stage for patients who have surgical resection after neoadjuvant therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preneoadjuvant treatment clinical T (cT) should be based on clinical or imaging findings.",
"     </li>",
"     <li>",
"      Postneoadjuvant treatment T should be based on clinical or imaging (ycT) or pathologic findings (ypT).",
"     </li>",
"     <li>",
"      A subscript is now added to the clinical N for both node negative and node positive patients to indicate whether the nodal diagnosis was derived from clinical examination, fine needle aspiration, core needle biopsy or sentinel lymph node biopsy.",
"     </li>",
"     <li>",
"      The posttreatment ypT is the largest contiguous focus of invasive cancer as defined histopathologically with a subscript to indicate the presence of multiple tumor foci.",
"     </li>",
"     <li>",
"      Posttreatment nodal metastases no greater than 0.2 mm are classified as ypN0(+). However, patients with this finding are not considered to have achieved a pathologic complete response (pCR).",
"     </li>",
"     <li>",
"      The degree of response to neoadjuvant treatment (complete, partial, no response) will now be recorded in the tumor registry.",
"     </li>",
"     <li>",
"      Patients are considered to have M1 (stage IV) breast cancer if metastases were detectable before neoadjuvant therapy, regardless of their status after neoadjuvant treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CURRENT (SEVENTH EDITION) TNM BREAST CANCER STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Primary tumor classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitions for tumor classification are the same whether assessed clinically or pathologically. A designation of cT or pT is used to indicate whether the staging is based on clinical or pathologic criteria. Pathologic classification is preferred when available.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tx &mdash; Primary tumor cannot be assessed",
"     </li>",
"     <li>",
"      T0 &mdash; No evidence of primary tumor",
"     </li>",
"     <li>",
"      Tis &mdash; Carcinoma in situ",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       Tis (DCIS)",
"      </strong>",
"      &mdash; Ductal carcinoma in situ",
"     </li>",
"     <li>",
"      <strong>",
"       Tis (LCIS)",
"      </strong>",
"      &mdash; Lobular carcinoma in situ",
"     </li>",
"     <li>",
"      <strong>",
"       Tis (Paget)",
"      </strong>",
"      &mdash; Paget disease of the nipple is",
"      <strong>",
"       not",
"      </strong>",
"      associated with invasive carcinoma",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      carcinoma in situ (DCIS",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      LCIS) in the underlying breast parenchyma. Carcinoma in the breast parenchyma associated with Paget disease is categorized based on the size and characteristics of the parenchymal disease, although the presence of Paget disease should still be noted",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T1 &mdash; Tumor &le;20 mm in greatest dimension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       T1mi",
"      </strong>",
"      &mdash; Tumor &le;1 mm in greatest dimension",
"     </li>",
"     <li>",
"      <strong>",
"       T1a",
"      </strong>",
"      &mdash; Tumor &gt;1 mm but &le;5 mm in greatest dimension",
"     </li>",
"     <li>",
"      <strong>",
"       T1b",
"      </strong>",
"      &mdash; Tumor &gt;5 mm but &le;10 mm in greatest dimension",
"     </li>",
"     <li>",
"      <strong>",
"       T1c",
"      </strong>",
"      &mdash; Tumor &gt;10 mm but &le;20 mm in greatest dimension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T2 &mdash; Tumor &gt;20 mm but &le;50 mm in greatest dimension",
"     </li>",
"     <li>",
"      T3 &mdash; Tumor &gt;50 mm in greatest dimension",
"     </li>",
"     <li>",
"      T4 &mdash; Tumor of any size with direct extension to the chest wall",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the skin (ulceration or skin nodules)*",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       T4a",
"      </strong>",
"      &mdash; Extension to chest wall, not including only pectoralis muscle",
"      <span class=\"nowrap\">",
"       adherence/invasion",
"      </span>",
"     </li>",
"     <li>",
"      <strong>",
"       T4b",
"      </strong>",
"      &mdash; Ulceration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      ipsilateral satellite nodules",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      edema (including peau d'orange) of the skin, which do not meet the criteria for inflammatory carcinoma",
"     </li>",
"     <li>",
"      <strong>",
"       T4c",
"      </strong>",
"      &mdash; Both (T4a and T4b)",
"     </li>",
"     <li>",
"      <strong>",
"       T4d",
"      </strong>",
"      &mdash; Inflammatory carcinoma**",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    *Note: Invasion of the dermis alone does not qualify as T4.",
"   </p>",
"   <p>",
"    **Note: Inflammatory carcinoma is restricted to cases with typical skin changes involving a third or more of the skin of the breast. While the histologic presence of invasive carcinoma invading dermal lymphatics is supportive of the diagnosis, it is not required, nor is dermal lymphatic invasion without typical clinical findings sufficient for a diagnosis of inflammatory breast cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Regional lymph nodes (N)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph node classification criteria differ depending on whether the nodes are clinically or pathologically assessed. A designation of cN or pN is used to make the distinction. Pathologic classification is preferred when available (",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Regional lymph nodes include axillary nodes, ipsilateral intramammary nodes, internal mammary nodes and supraclavicular nodes. Intramammary nodes reside within the breast tissue and are coded as axillary lymph nodes for staging purposes. Supraclavicular lymph nodes are classified as regional lymph nodes for staging purposes. Metastases to any other lymph node, including cervical, or contralateral axillary lymph nodes are classified as distant (M1).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Clinical classification of regional lymph nodes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      cNX &mdash; Regional lymph nodes cannot be assessed (eg, previously removed)",
"     </li>",
"     <li>",
"      cN0 &mdash; No regional lymph node metastases",
"     </li>",
"     <li>",
"      cN1 &mdash; Metastasis to movable ipsilateral level I, II axillary lymph nodes(s)",
"     </li>",
"     <li>",
"      cN2 &mdash; Metastasis to ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected* ipsilateral internal mammary nodes in the absence of clinically evident axillary node metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       cN2a",
"      </strong>",
"      &mdash; Metastasis to ipsilateral level I, II axillary lymph nodes fixed to one another (matted) or to other structures",
"     </li>",
"     <li>",
"      <strong>",
"       cN2b",
"      </strong>",
"      &mdash; Metastasis only in clinically detected*** ipsilateral internal mammary nodes, and in the absence of clinically evident axillary node metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      cN3 &mdash; Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) with or without level I, II axillary lymph node involvement; or in clinically detected* ipsilateral internal mammary lymph node(s) with clinically evident level I, II axillary lymph node metastases; or metastases in ipsilateral supraclavicular lymph node(s) with or without axillary or internal mammary lymph node involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       cN3a",
"      </strong>",
"      &mdash; Metastasis to ipsilateral infraclavicular lymph node(s)",
"     </li>",
"     <li>",
"      <strong>",
"       cN3b",
"      </strong>",
"      &mdash; Metastasis to ipsilateral internal mammary lymph node(s) and axillary lymph nodes",
"     </li>",
"     <li>",
"      <strong>",
"       cN3c",
"      </strong>",
"      &mdash; Metastasis in ipsilateral supraclavicular lymph node(s)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pathologic classification of regional lymph nodes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      pNX &mdash; Regional lymph nodes cannot be assessed (eg, previously removed, or not removed for pathologic study)",
"     </li>",
"     <li>",
"      pN0 &mdash; No regional lymph node metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       pNO",
"      </strong>",
"      &mdash; No regional lymph node metastasis identified histologically",
"     </li>",
"     <li>",
"      <strong>",
"       pNO(i-)",
"      </strong>",
"      &mdash; No regional lymph node metastases histologically, negative IHC",
"     </li>",
"     <li>",
"      <strong>",
"       pN0(i+)",
"      </strong>",
"      &mdash; Malignant cells in regional lymph node(s) no greater than 0.2 mm (detected by H&amp;E or IHC including ITC)",
"     </li>",
"     <li>",
"      <strong>",
"       pNO(mol-)",
"      </strong>",
"      &mdash; No regional lymph node metastases histologically, negative molecular findings (RT-PCR)",
"     </li>",
"     <li>",
"      <strong>",
"       pNO(mol+)",
"      </strong>",
"      &mdash; Positive molecular findings (RT-PCR), but no regional lymph node metastases detected by histology or IHC",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      pN1 &mdash; Micrometastases, or metastases in one to three axillary lymph nodes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      in internal mammary nodes with metastases detected by sentinel lymph node biopsy but not clinically detected**",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       pN1mi",
"      </strong>",
"      &mdash; Micrometastases (greater than 0.2 mm",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      more than 200 cells, but none greater than 2.0 mm)",
"     </li>",
"     <li>",
"      <strong>",
"       pN1a",
"      </strong>",
"      &mdash; Metastases in 1 to 3 axillary lymph nodes, at least one metastasis greater than 2.0 mm",
"     </li>",
"     <li>",
"      <strong>",
"       pN1b",
"      </strong>",
"      &mdash; Metastases in internal mammary nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected**",
"     </li>",
"     <li>",
"      <strong>",
"       pN1c",
"      </strong>",
"      &mdash;Metastases in one to three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected**",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      pN2 &mdash; Metastases in four to nine axillary lymph nodes, or in clinically detected**** internal mammary lymph nodes in the absence of axillary lymph node metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       pN2a",
"      </strong>",
"      &mdash; Metastases in four to nine axillary lymph nodes (at least one tumor deposit greater than 2.0 mm)",
"     </li>",
"     <li>",
"      <strong>",
"       N2b",
"      </strong>",
"      &mdash; Metastasis only in clinically detected*** ipsilateral internal mammary nodes and in the absence of clinically evident axillary node metastases",
"     </li>",
"     <li>",
"      <strong>",
"       pN2b",
"      </strong>",
"      &mdash; Metastases in clinically detected*** internal mammary lymph nodes in the absence of axillary lymph node metastases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      pN3 &mdash; Metastases in 10 or",
"      <strong>",
"       more",
"      </strong>",
"      axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or in clinically detected",
"      <strong>",
"       ***",
"      </strong>",
"      ipsilateral internal mammary lymph nodes in the presence of 1 or more positive level I, II axillary lymph nodes; or in more than 3 axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected**; or in ipsilateral supraclavicular lymph nodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       N3a &mdash;",
"      </strong>",
"      Metastases in 10 or more axillary lymph nodes (at least one tumor deposit greater than 2.0 mm); or metastases to the infraclavicular (level III axillary lymph) nodes",
"     </li>",
"     <li>",
"      <strong>",
"       pN3b &mdash;",
"      </strong>",
"      Metastases in clinically detected*** ipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes; or in more than three axillary lymph nodes and in internal mammary lymph nodes with micrometastases or macrometastases detected by sentinel lymph node biopsy but not clinically detected**",
"     </li>",
"     <li>",
"      <strong>",
"       pN3c &mdash;",
"      </strong>",
"      Metastases in ipsilateral supraclavicular lymph nodes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    * Classification is based on axillary lymph node dissection with or without sentinel lymph node biopsy. Classification based solely on sentinel lymph node biopsy without subsequent axillary lymph node dissection is designated (sn) for \"sentinel node,\" for example, pN0(sn).",
"   </p>",
"   <p>",
"    ** Note: Not clinically detected is defined as not detected by imaging studies (excluding lymphoscintigraphy) or not detected by clinical examination.",
"   </p>",
"   <p>",
"    *** Note: Clinically detected is defined as detected by imaging studies (excluding lymphoscintigraphy) or by clinical examination and having characteristics highly suspicious for malignancy or a presumed pathologic macrometastasis based on fine needle aspiration biopsy with cytologic examination. Confirmation of clinically detected metastatic disease by fine needle aspiration without excision biopsy is designated with an (f) suffix, for example, cN3a(f). Excisional biopsy of a lymph node or biopsy of a sentinel node, in the absence of assignment of a pT, is classified as a clinical N, for example, cN1. Information regarding the confirmation of the nodal status will be designated in site-specific factors as clinical, fine needle aspiration, core biopsy, or sentinel lymph node biopsy. Pathologic classification (pN) is used for excision or sentinel lymph node biopsy only in conjunction with a pathologic T assignment.",
"   </p>",
"   <p>",
"    **** Note: Isolated tumor cell clusters (ITC) are defined as small clusters of cells not greater than 0.2 mm, or single tumor cells, or a cluster of fewer than 200 cells in a single histologic cross-section. ITCs may be detected by routine histology or by immunohistochemical (IHC) methods. Nodes containing only ITCs are excluded from the total positive node count for purposes of N classification, but should be included in the total number of nodes evaluated",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Distant metastasis (M)",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M0 &mdash; No clinical or radiographic evidence of distant metastases (no pathologic M0; use clinical M to complete stage group)",
"     </li>",
"     <li>",
"      cMO(i+) &mdash; No clinical or radiographic evidence of distant metastases, but deposits of molecularly or microscopically-detected tumor cells in circulating blood, bone marrow or other nonregional nodal tissue that are no larger than 0.2 mm in a patient without symptoms or signs of metastases",
"     </li>",
"     <li>",
"      M1 &mdash; Distant detectable metastases as determined by classic clinical and radiographic means",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      histologically proven larger than 0.2 mm",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     STAGE GROUPINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"     table 1",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Stage 0",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Tis N0 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Stage IA",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;T1 N0 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Stage IB",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;TO N1mi MO",
"   </p>",
"   <p>",
"    &nbsp;T1 N1mi M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Stage IIA",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;T0 N1 MO",
"   </p>",
"   <p>",
"    &nbsp;T1 N1 M0",
"   </p>",
"   <p>",
"    &nbsp;T2 N0 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Stage IIB",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;T2 N1 M0",
"   </p>",
"   <p>",
"    &nbsp;T3 N0 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Stage IIIA",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;T0 N2 M0",
"   </p>",
"   <p>",
"    &nbsp;T1 N2 M0",
"   </p>",
"   <p>",
"    &nbsp;T2 N2 M0",
"   </p>",
"   <p>",
"    &nbsp;T3 N1 M0",
"   </p>",
"   <p>",
"    &nbsp;T3 N2 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stage IIIB",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;T4 N0 M0",
"   </p>",
"   <p>",
"    &nbsp;T4 N1 M0",
"   </p>",
"   <p>",
"    &nbsp;T4 N2 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Stage IIIC",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Any T N3 M0",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Stage IV",
"    </span>",
"   </p>",
"   <p>",
"    &nbsp;Any T Any N M1",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     PREVIOUS STAGING SYSTEM (SIXTH EDITION)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important changes in the sixth edition, published in 2002, as compared to the 1997 classification included [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24278/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dividing the N staging category into three categories based on the number of axillary lymph nodes involved",
"     </li>",
"     <li>",
"      Size-based discrimination between micrometastases and isolated tumor cells, identifiers to indicate usage of sentinel lymph node dissection and immunohistochemical or molecular techniques",
"     </li>",
"     <li>",
"      Reclassification of metastasis to internal mammary nodes, and supraclavicular nodes (Designated N3 rather than M1 disease) (",
"      <a class=\"graphic graphic_table graphicRef73355 \" href=\"UTD.htm?15/58/16303\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24278/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       \"Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The tumor node metastasis (TNM) staging system for breast cancer classifies tumors on the basis of the primary tumor type (invasive or in situ) and size (T), the presence or absence of regional lymph node involvement (N), and the presence or absence of distant metastases (M). The overall stage of the tumor (stage I through IV) depends upon the particular combination of T, N, and M characteristics. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'TNM staging system'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The TNM staging system estimates predicted survival, but should not be used alone to dictate treatment. Periodic revisions are necessary because advanced imaging techniques and treatments continue to evolve and impact survival. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Revisions in breast cancer staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most recent version of the TNM staging system is the Seventh edition of the \"TNM Classification of Malignant Tumors\". It became effective January 1, 2010 and includes new tumor stage groupings and refinements of the T and M descriptors (",
"      <a class=\"graphic graphic_table graphicRef65393 \" href=\"UTD.htm?29/14/29920\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef73355 \" href=\"UTD.htm?15/58/16303\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Current (seventh edition) TNM breast cancer staging system'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (2002) and Seventh Edition (2010) published by Springer-Verlag New York, Inc.",
"   </p>",
"   <p>",
"    The author of this topic review, Dr. Daniel Hayes, served as the Chair of the Committee on Breast Cancer Staging for the Seventh Edition Site Task Force.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 7th edition, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer-Verlag, New York 2010. p.347.",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer). Cancer Staging Manual, 6th edition, Greene FL, Page DL, Fleming ID, et al (Eds), Springer-Verlag, New York 2002. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24278/abstract/3\">",
"      Woodward WA, Strom EA, Tucker SL, et al. Changes in the 2003 American Joint Committee on Cancer staging for breast cancer dramatically affect stage-specific survival. J Clin Oncol 2003; 21:3244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24278/abstract/4\">",
"      Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20:3628.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 800 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-22FFA76FCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24278=[""].join("\n");
var outline_f23_45_24278=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TNM STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL VERSUS PATHOLOGIC STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      REVISIONS IN BREAST CANCER STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Changes in Tumor (T) classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Changes in Nodes (N) classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Changes in Metastases (M) classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Changes in postneoadjuvant therapy (yc or ypTNM) classification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CURRENT (SEVENTH EDITION) TNM BREAST CANCER STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Primary tumor classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Regional lymph nodes (N)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Clinical classification of regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pathologic classification of regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Distant metastasis (M)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      STAGE GROUPINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Stage 0",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Stage IA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Stage IB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Stage IIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Stage IIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Stage IIIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stage IIIB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Stage IIIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Stage IV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      PREVIOUS STAGING SYSTEM (SIXTH EDITION)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/14/29920\" title=\"table 1\">",
"      TNM stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/58/16303\" title=\"table 2\">",
"      2002 TNM breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24279="Procarbazine: Drug information";
var content_f23_45_24279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Procarbazine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5909?source=see_link\">",
"    see \"Procarbazine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39862?source=see_link\">",
"    see \"Procarbazine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Matulane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Matulane&reg;;",
"     </li>",
"     <li>",
"      Natulan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F213736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Alkylating Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chemotherapy:",
"     </b>",
"     Oral: Initial: 2-4 mg/kg/day in single or divided doses for 7 days then increase dose to 4-6 mg/kg/day until response is obtained or leukocyte count decreased &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     or the platelet count decreased &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ; maintenance: 1-2 mg/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F213722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39862?source=see_link\">",
"      see \"Procarbazine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual protocols. Manufacturer states that the dose is based on patient's ideal weight if the patient is obese or has abnormal fluid retention. Other studies suggest that ideal body weight may not be necessary. Oral (may be given as a single daily dose or in 2-3 divided doses): Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      BMT aplastic anemia conditioning regimen (unlabeled use):",
"     </b>",
"     12.5 mg/kg/day every other day for 4 doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin's disease:",
"     </b>",
"     MOPP/IC-MOPP regimens: 100 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day for 14 days and repeated every 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Neuroblastoma and medulloblastoma (unlabeled use):",
"     </b>",
"     Doses as high as 100-200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day once daily have been used.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing; use with caution. Adjust for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F213705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with caution; may result in increased toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F213706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain dosing adjustment guidelines; use with caution; may result in increased toxicity. The following guidelines have been used by some clinicians:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Floyd, 2006:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases 1.6-6 times ULN: Administer 75% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transaminases &gt;6 times ULN: Use clinical judgment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;5 mg/dL or transaminases &gt;3 times ULN: Avoid use",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;\">",
"     King, 2001: Serum bilirubin &gt;5 mg/dL or transaminases &gt;180 units/L: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Matulane&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3415044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be given as a single daily dose or in 2-3 divided doses.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of Hodgkin's disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F213733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of non-Hodgkin's lymphoma, brain tumors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F213744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Procarbazine may be confused with dacarbazine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F213734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most frequencies not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, flushing, hypotension, syncope, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Apprehension, ataxia, chills, coma, confusion, depression, dizziness, drowsiness, fatigue, fever, hallucination, headache, insomnia, lethargy, nervousness, nightmares, pain, seizure, slurred speech",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, hyperpigmentation, petechiae, pruritus, purpura, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gynecomastia (in prepubertal and early pubertal males)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia; hemolysis (in patients with G6PD deficiency); hemolytic anemia; myelosuppression (leukopenia, anemia, thrombocytopenia); pancytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysphagia, hematemesis, melena; nausea and vomiting ([60% to 90%], increasing the dose in a stepwise fashion over several days may minimize); stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Azoospermia (reported with combination chemotherapy), hematuria, nocturia, polyuria, reproductive dysfunction (&gt;10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatic dysfunction, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, falling, foot drop, myalgia, neuropathy, paresthesia, reflex diminished, tremor, unsteadiness, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, inability to focus, nystagmus, papilledema, photophobia, retinal hemorrhage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, epistaxis, hemoptysis, hoarseness, pleural effusion, pneumonitis, pulmonary toxicity (&lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction, diaphoresis, herpes, infection, secondary malignancies (2% to 15%; reported with combination therapy)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to procarbazine or any component of the formulation; pre-existing bone marrow aplasia; ethanol ingestion; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression: May occur 2-8 weeks after treatment initiation; allow &ge;1 month interval between radiation therapy or myelosuppressive chemotherapy and initiation of treatment. Withhold treatment for leukopenia (WBC &lt;4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or thrombocytopenia (platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS toxicity: Withhold treatment for CNS toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diarrhea: Withhold treatment for diarrhea.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Disulfiram-like reaction: Avoid ethanol consumption, may cause disulfiram-like reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemolysis: May cause hemolysis and/or presence of Heinz inclusion bodies in erythrocytes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemorrhage: Withhold treatment for hemorrhage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity: Withhold treatment for hypersensitivity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infertility: May cause infertility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Secondary malignancies: Possibly carcinogenic; acute leukemia and lung cancer have been reported following use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stomatitis: Withhold treatment for stomatitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; MAO inhibitor activity: Possesses MAO inhibitor activity and has potential for severe drug and food interactions; follow MAO-I diet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may enhance the adverse/toxic effects of procarbazine or cause a disulfiram reaction. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Supplements containing caffeine, tyrosine, tryptophan, or phenylalanine may increase the risk of severe side effects (eg, hypertensive reactions, serotonin syndrome). Echinacea may diminish the therapeutic effect of immunosuppressants. Management: Avoid supplements containing caffeine, tyrosine, tryptophan, or phenylalanine. Consider avoiding echinacea.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3415040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have demonstrated teratogenic effects. There are no adequate and well-controlled studies in pregnant women. There are, however, case reports of fetal malformations in the offspring of pregnant women exposed to procarbazine as part of a combination chemotherapy regimen. Women of childbearing potential should avoid becoming pregnant during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3196444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid tyramine-containing foods/beverages. Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Matulane Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (100): $6217.20",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelet and reticulocyte count, urinalysis, liver function test, renal function test.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Indicarb (IN);",
"     </li>",
"     <li>",
"      Matulane (PH);",
"     </li>",
"     <li>",
"      Natulan (AE, AR, AT, AU, BE, BG, BH, CH, CY, CZ, DE, DK, EG, ES, FI, FR, GB, GH, GR, HN, HR, HU, IE, IL, IQ, IR, IT, JO, KW, LB, LU, LY, MY, NL, NO, OM, PK, PL, PT, QA, RU, SA, SE, SY, TR, TZ, UG, YE, ZM);",
"     </li>",
"     <li>",
"      Natulanar (BR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism of action is not clear, methylating of nucleic acids; inhibits DNA, RNA, and protein synthesis; may damage DNA directly and suppresses mitosis; metabolic activation required by host",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid and complete",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses blood-brain barrier; equilibrates between plasma and CSF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and renal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine and respiratory tract (&lt;5% as unchanged drug, 70% as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Floyd J, Mirza I, Sachs B, et al, \"Hepatotoxicity of Chemotherapy,\"",
"      <i>",
"       Semin Oncol",
"      </i>",
"      , 2006, 33(1):50-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/16473644/pubmed\" id=\"16473644\" target=\"_blank\">",
"        16473644",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2001, 6(2):162-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/11306728/pubmed\" id=\"11306728\" target=\"_blank\">",
"        11306728",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Longo DL, Young RC, Wesley M, et al, &ldquo;Twenty Years of MOPP Therapy for Hodgkin's Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1986, 4(9):1295-306.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/3528400/pubmed\" id=\"3528400\" target=\"_blank\">",
"        3528400",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodriguez LA, Prados M, Silver P, et al, &ldquo;Re-evaluation of Procarbazine for the Treatment of Recurrent Malignant Central Nervous System Tumors,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 1989, 64(12):2420-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/2555038/pubmed\" id=\"2555038\" target=\"_blank\">",
"        2555038",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/10192596/pubmed\" id=\"10192596\" target=\"_blank\">",
"        10192596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spivack SD, &ldquo;Procarbazine,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1974, 81:795-800.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/4611297/pubmed\" id=\"4611297\" target=\"_blank\">",
"        4611297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toth B, &ldquo;A Review of the Antineoplastic Action of Certain Hydrazines and Hydrazine-Containing Natural Products,&rdquo;",
"      <i>",
"       In Vivo",
"      </i>",
"      , 1996, 10(1):65-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/8726813/pubmed\" id=\"8726813\" target=\"_blank\">",
"        8726813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Shulman KI, Tailor SA, et al, &ldquo;Tyramine Content of Previously Restricted Foods in Monoamine Oxidase Inhibitor Diets,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1996, 16(5):383-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?23/45/24279/abstract-text/8889911/pubmed\" id=\"8889911\" target=\"_blank\">",
"        8889911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9815 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24279=[""].join("\n");
var outline_f23_45_24279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709348\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213699\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213700\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213736\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213703\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213722\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213704\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213705\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213706\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213682\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213667\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415044\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213683\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213733\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213744\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213734\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213687\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213671\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299945\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213676\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213696\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213678\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415040\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213710\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3196444\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323725\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213680\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038781\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213670\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213686\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9815\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9815|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/49/5909?source=related_link\">",
"      Procarbazine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39862?source=related_link\">",
"      Procarbazine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24280="Congenital and acquired goiter in children";
var content_f23_45_24280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital and acquired goiter in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24280/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/45/24280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children may have goiters that are diffuse or nodular, and the goiters may be associated with normal, decreased, or increased thyroid hormone production. The causes of goiter in children and adults are similar, but their relative frequency varies substantially. In the United States, for example, most children with a goiter have chronic autoimmune thyroiditis, whereas among adults, nontoxic nodular goiters predominate.",
"   </p>",
"   <p>",
"    Goiter may be present at birth or detected at any age thereafter. The goiter may be caused by increased thyrotropin (TSH) secretion (acting as a thyroid growth factor) resulting from hypothyroidism; antibodies that activate TSH receptors (Graves' disease) with increased thyroid hormone secretion; or TSH-independent processes, such as inflammation associated with autoimmune thyroiditis, benign and malignant tumors, and infiltrative disease.",
"   </p>",
"   <p>",
"    Once a goiter is detected, the appropriate diagnostic evaluation is aimed at identifying the underlying cause and assessing thyroid function. Both of these factors will determine management. This topic review will consider congenital and acquired goiters, independent of their function, in infants and children.",
"   </p>",
"   <p>",
"    Thyroid nodules and cancers, and the causes of hypothyroidism and hyperthyroidism in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=see_link\">",
"     \"Thyroid nodules and cancer in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THYROID SIZE IN INFANTS AND CHILDREN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mean (&plusmn;SD) thyroid volume, measured by ultrasonography, in 68 term neonates in Chicago was 0.9 &plusmn; 0.2 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/1\">",
"     1",
"    </a>",
"    ]. In an extensive study of 7- to 14-year-old children from an iodine-sufficient area of Italy, the mean thyroid volume increased with age from 3.1 to 6.3 mL (",
"    <a class=\"graphic graphic_table graphicRef79028 \" href=\"UTD.htm?22/30/23019\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/2\">",
"     2",
"    </a>",
"    ]. Thyroid size correlates with body surface area; among children 6 to 14 years of age, the upper 95th percentile was 6.2 mL per m",
"    <sup>",
"     2",
"    </sup>",
"    in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/3\">",
"     3",
"    </a>",
"    ]. In a report of 6- to 12-year old children from Japan, where intake of iodine is relatively high (median urinary iodine 281.6",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    thyroid volumes were smaller, increasing from 1.5 mL to 3.8 mL over this age period [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/4\">",
"     4",
"    </a>",
"    ]. Clinically, we use the \"rule of thumb\" to evaluate thyroid size in older children: each lobe of the normal thyroid gland is approximately the size of the terminal phalanx of the child's thumb. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CONGENITAL GOITER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the causes of congenital goiter are sometimes hereditary (",
"    <a class=\"graphic graphic_table graphicRef71540 \" href=\"UTD.htm?19/4/19531\">",
"     table 2",
"    </a>",
"    ), the enlarged thyroid gland, and the thyroid dysfunction that often accompanies it, may not be evident at birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Inborn errors of thyroid hormone production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic defects in each step of thyroid hormone production (dyshormonogenesis) have been described. These defects are inherited as autosomal recessive traits. All result in varying degrees of hypothyroidism, and may be detected by newborn screening [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"     \"Thyroid hormone synthesis and physiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The defects include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A defect in iodine transport (or trapping) because of a mutation in the",
"      <span class=\"nowrap\">",
"       Na/I",
"      </span>",
"      symporter (NIS) gene [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/6\">",
"       6",
"      </a>",
"      ]. Infants with these mutations tend to have a variable degree of congenital hypothyroidism and goiter [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/7\">",
"       7",
"      </a>",
"      ]; a review of 12 different NIS molecular defects did not find a clear genotype-phenotype correlation [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Iodine organification and coupling defects because of deficiency in the quantity or activity of thyroid peroxidase [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/9\">",
"       9",
"      </a>",
"      ] or in",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"       hydrogen peroxide",
"      </a>",
"      generation. The latter defect caused by mutations in the dual oxidase 2 (DUOX2) gene tends to produce milder, sometimes transient congenital hypothyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pendred syndrome (",
"      <a class=\"external\" href=\"file://omim.org/entry/274600\">",
"       MIM #274600",
"      </a>",
"      ) is characterized by both goiter and sensorineural deafness (not caused by hypothyroidism). It is caused by a biallelic mutation in the SLC26A4 gene (solute carrier family 26, member 4), located on chromosome 7 (7q31) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/7,11\">",
"       7,11",
"      </a>",
"      ]. The encoded protein, pendrin, is a multifunctional anion exchanger. It is expressed in the apical membrane of the thyroid and appears to mediate iodide efflux into the lumen. Pendrin is also expressed in the inner ear and is important for normal endolymph composition and maintenance of the endocochlear potential [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/11\">",
"       11",
"      </a>",
"      ]. These children have a mutation in a transport protein (\"pendrin\") on chromosome 7q, which transports iodide into the exocytotic vesicles in which thyroid hormone is synthesized [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/12\">",
"       12",
"      </a>",
"      ]. This chloride-iodide transport protein functions in both the thyroid gland and inner ear [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Defects in thyroglobulin biosynthesis result from decreased production or the production of a truncated molecule or one which has amino-acid substitutions within it [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/14\">",
"       14",
"      </a>",
"      ]. The thyroglobulin protein may be synthesized, but it cannot be secreted [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/15\">",
"       15",
"      </a>",
"      ]. The result is decreased formation of thyroxine (T4) and triiodothyronine (T3) within the thyroglobulin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=see_link\">",
"       \"Thyroid hormone synthesis and physiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Defects in iodotyrosine deiodinase result from mutations in the DEHAL1 gene, so that the iodine contained in the iodotyrosine residues of thyroglobulin is not recycled [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders account for approximately 10 to 15 percent of cases of congenital hypothyroidism. Elucidation of specific defects requires thyroid radionuclide imaging or ultrasonography, measurements of serum thyroglobulin and iodothyronines, and gene analysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"     \"Clinical features and detection of congenital hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally this type of disorder is identified prenatally, when a fetus is diagnosed with nonimmune goitrous hypothyroidism and the mother is euthyroid. Case reports have described prenatal treatment of such cases by injecting T4 into the amniotic fluid. In the largest such series, fetal goiter size decreased during treatment, and there were no adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/17\">",
"     17",
"    </a>",
"    ]. However, the infants were still hypothyroid at birth, suggesting that the treatment did not fully correct the hypothyroidism. There are inadequate data to suggest whether prenatal treatment improves obstetrical or cognitive outcomes in the offspring, or to determine the optimal dosing regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Transplacental passage of maternal thyroid-reactive antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with chronic autoimmune thyroiditis or Graves' disease may produce antibodies that cross the placenta, resulting in fetal and neonatal goiter and thyroid dysfunction, depending upon the type of antibody.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TSH-receptor blocking antibodies &mdash; Transplacental passage of TSH-receptor antibodies that block the action of TSH can cause fetal hypothyroidism, which is occasionally accompanied by goiter (though typically the gland is normal size or small). These antibodies are detected in approximately 1:100,000 newborn infants [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/18\">",
"       18",
"      </a>",
"      ]. This disorder is confirmed by laboratory testing showing elevated thyrotropin-binding inhibitory immunoglobulins (TBII). The hypothyroidism and goiter in these infants are transient, typically resolving in three to six months as the transplacentally acquired antibodies are cleared. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"       \"Clinical features and detection of congenital hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TSH-receptor stimulating antibodies &mdash; Transplacental passage of TSH-receptor antibodies that mimic the action of TSH cause fetal and neonatal Graves' hyperthyroidism and goiter. The mother may have had hyperthyroidism during the pregnancy, or she may have had it in the past and have been treated by thyroidectomy or radioactive iodine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neonatal Graves' disease occurs in approximately 1:25,000 neonates. The goiters in these infants may be detected by physical examination or by ultrasonography. Laboratory testing showing elevated thyrotropin stimulating immunoglobulin (TSI) in mother or neonate will confirm Graves' disease. Neonatal Graves' hyperthyroidism and goiter resolve in three to six months as the antibodies are cleared. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Maternal ingestion of antithyroid drugs and other goitrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antithyroid drugs",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    , and carbimazole all cross the placenta and can cause fetal hypothyroidism and goiter. Other compounds that can cross the placenta and cause fetal hypothyroidism and goiter are iodine-rich drugs such as expectorants,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/41/9882?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and skin disinfectants. One case of a perinatal goiter was caused by excess maternal iodine ingestion due to an error in manufacturing a prenatal vitamin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/19\">",
"     19",
"    </a>",
"    ]. Neonates given oral or topical iodine or bathed with iodine soon after birth can develop a goiter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Activating mutations of the TSH-receptor (congenital nonimmune hyperthyroidism)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Germline mutations of the TSH-receptor gene that result in constitutive activation of the receptor are a rare cause of diffuse goiter and hyperthyroidism, which may be present at birth or first become evident years or even decades later [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/20\">",
"     20",
"    </a>",
"    ]. These mutations are inherited as autosomal dominant traits; as a result, there may be a family history of hyperthyroidism and goiter.",
"   </p>",
"   <p>",
"    Although antithyroid drug therapy is effective, the disorder is permanent, and hyperthyroidism will recur if the drug is discontinued. Consequently, ablative treatment such as thyroidectomy is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     McCune-Albright syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatic mutations in the alpha subunit of the guanine nucleotide-binding protein (G protein) are present in the thyroid gland in infants and children with the McCune-Albright syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/21\">",
"     21",
"    </a>",
"    ]. They are activating mutations, and therefore result in thyroid hyperplasia or formation of nodules and, ultimately, in toxic nodular goiters [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/22\">",
"     22",
"    </a>",
"    ]. Other features of the syndrome, such as caf&eacute;-au-lait skin pigmentation, precocious puberty, and polyostotic fibrous dysplasia, are usually present and provide clues to the underlying diagnosis. The hyperthyroidism is permanent, and some form of thyroid ablation is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid hemiagenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hemiagenesis may cause unilateral goiter in neonates because of compensatory hypertrophy of the contralateral lobe. In Sicily, screening of 24,032 children identified 12 cases of hemiagenesis (1:2000), all resulting from absence of the left lobe. The average TSH was 2.8 versus 1.9",
"    <span class=\"nowrap\">",
"     mU/L",
"    </span>",
"    for age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, teratomas of the thyroid present in the neonatal period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ACQUIRED GOITER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the causes of acquired goiter in infants and children, chronic autoimmune (Hashimoto's) thyroiditis and colloid goiter are the most common in the United States (",
"    <a class=\"graphic graphic_table graphicRef77604 \" href=\"UTD.htm?6/0/6156\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chronic autoimmune (Hashimoto's) thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1 to 2 percent of school-aged children have clinical evidence of chronic autoimmune thyroiditis, also known as chronic lymphocytic thyroiditis, [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/24\">",
"     24",
"    </a>",
"    ] and 5 to 6 percent have serologic evidence of this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/25\">",
"     25",
"    </a>",
"    ]. It is more common in girls than boys and whites than blacks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link&amp;anchor=H4#H4\">",
"     \"Acquired hypothyroidism in childhood and adolescence\", section on 'Chronic autoimmune thyroiditis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25762082\">",
"    <span class=\"h3\">",
"     Associations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic autoimmune thyroiditis is especially common in children with certain chromosomal disorders, including trisomy 21 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/26\">",
"     26",
"    </a>",
"    ], Turner's syndrome, and perhaps Klinefelter's syndrome, and is an integral component of the autoimmune polyglandular syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25762089\">",
"    <span class=\"h3\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation is a firm, bosselated (bumpy), nontender goiter discovered incidentally by a parent or during a routine examination [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/27\">",
"     27",
"    </a>",
"    ]. The goiter is usually diffuse, but may be irregular or even nodular. Most of the children are euthyroid, but some have subclinical or overt hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/28\">",
"     28",
"    </a>",
"    ]. The most common manifestations of the latter are slow growth velocity, short stature, and delayed pubertal development. Autoimmune thyroiditis can also cause thyroid atrophy rather than goiter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25762096\">",
"    <span class=\"h3\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with a goiter suspected to be a result of Hashimoto's thyroiditis, the initial laboratory evaluation should include assessment of thyroid function (serum TSH and free T4) and antithyroid antibodies. Routine imaging, either by ultrasonography or radionuclide scan is generally not indicated. If thyroid ultrasound is performed, this typically shows scattered hypoechogenicity. In children with other evidence for chronic autoimmune thyroiditis, if the initial ultrasound is normal, on follow-up examination 50 percent will show typical ultrasound changes within seven months [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 85 to 90 percent of children with chronic autoimmune thyroiditis have high serum concentrations of antithyroid peroxidase (TPO) antibodies, and nearly as many have high serum concentrations of antithyroglobulin antibodies. Thyrotropin receptor blocking antibodies have been reported in 9.2 percent of children with chronic autoimmune thyroiditis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/30\">",
"     30",
"    </a>",
"    ]. Such children are more likely to have an elevated serum TSH level, indicating hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25762103\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;T4 treatment is indicated in patients with elevated serum TSH concentrations, in whom it may result in a decrease in goiter size. Patients who are euthyroid may also respond to treatment with T4 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the patient has a markedly asymmetric goiter or a prominent nodule, or a smaller nodule that enlarges during follow-up, fine-needle aspiration (FNA) biopsy is indicated. In a report of 365 children with autoimmune thyroiditis, 115 had nodules (31.5 percent); FNA led to discovery of papillary thyroid cancer in 11 patients (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Colloid goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colloid goiters are diffuse goiters, usually occurring in adolescent girls. They may be familial, with an autosomal dominant pattern of inheritance. In a study of female twins in Denmark, for example, the cumulative concordance rates for goiter in monozygotic and dizygotic twins were 53 percent and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cause of colloid goiter in children is not known. Although the thyroid gland is usually diffusely enlarged, it can be asymmetric or nodular. Thyroid function is normal, and serum antithyroid antibody concentrations are normal. Histologic examination reveals flattened epithelium, variable follicular size, and dense colloid. These goiters usually gradually decrease in size over several years; the course is not altered by T4 therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Iodine-deficiency goiter",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 1.5 billion people worldwide are at risk for iodine deficiency and, therefore, for iodine-deficiency (endemic) goiter. Iodine supplementation, primarily through iodized salt, has eradicated iodine-deficiency goiter in the United States. Median urinary iodine excretion in adults decreased by approximately 50 percent in the United States from the 1970s to the 1990s (from 320 to 145",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [2.6 to 1.2",
"    <span class=\"nowrap\">",
"     micromol/L]),",
"    </span>",
"    indicative of a substantial decline in iodine intake [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/35\">",
"     35",
"    </a>",
"    ]. Values less than 50",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (0.4",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    are associated with goiter, raising the possibility of recrudescence of endemic goiter. It appears that this decrease has stabilized, as the most recent survey (2001 to 2002) reports median urinary iodine excretion of 167.8",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link\">",
"     \"Iodine deficiency disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with moderate or severe iodine deficiency and goiter have subclinical or mild overt hypothyroidism, but their serum T3 concentrations may be normal or high because of preferential thyroidal T3 secretion. They can be treated with either iodine or T4. Vitamin A deficiency increased the risk for goiter formation in severe iodine-deficient children by increasing TSH stimulation, which reduced the risk for hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/37\">",
"     37",
"    </a>",
"    ]. Eradication of endemic iodine-deficiency goiter can take up to a decade after initiation of iodine prophylaxis in a geographic region [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iodine-deficiency goiter can occur in neonates, but it is rare. Many neonates and infants with endemic cretinism do not have a goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/39\">",
"     39",
"    </a>",
"    ] because they are no longer hypothyroid (neurologic cretinism) or their thyroid has been destroyed (hypothyroid cretinism).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ingestion of goitrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common goitrogen ingested by children is iodine, most often in the form of iodine-containing expectorants for chronic reactive airways disease or cystic fibrosis. Another source of iodine is kelp. Most children with iodine-induced goiters probably have chronic autoimmune thyroiditis; they develop a goiter because the damaged thyroid cannot adapt to a high iodine intake.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/38/1639?source=see_link\">",
"     Lithium",
"    </a>",
"    carbonate may cause hypothyroidism and goiter in children as well as in adults. Cessation of the offending drug or food supplement should result in restoration of normal thyroid function and diminution of the goiter. Interferon treatment may be associated with the development of thyroiditis and disturbances of thyroid function (either hypo- and hyperthyroidism), and, in a few patients, the development of a goiter [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain foods (cassava and millet) contain goitrogenic substances. Consumed alone, these substances are unlikely to cause goiter, but they can contribute to goiter formation when iodine intake is marginal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Subacute granulomatous thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subacute granulomatous thyroiditis, also known as DeQuervain's disease, is uncommon in children. It should be suspected in any child with a painful, tender goiter. Its course in children is similar to that in adults, with an early painful, hyperthyroid phase followed by euthyroid and then hypothyroid phases, and finally recovery. Treatment consists of a nonsteroidal anti-inflammatory drug or, in very symptomatic patients,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    . If patients have symptoms of hyperthyroidism with a suppressed serum TSH level, they may be treated with a beta-adrenergic receptor blocker, while during the hypothyroid phase they may require thyroid hormone replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=see_link\">",
"     \"Subacute thyroiditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Acute suppurative thyroiditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute bacterial infection resulting in an abscess of the thyroid is also uncommon in children. The clinical presentation is characterized by abrupt onset of painful, tender swelling of one lobe of the thyroid accompanied by fever, chills, sore throat, hoarseness, and dysphagia. The left lobe is more commonly involved, and a pyriform sinus fistula is usually present (it can be detected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    swallow or ultrasonography). Rarely, acute suppurative thyroiditis is associated with transient hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10312?source=see_link\">",
"     \"Suppurative thyroiditis in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Thyroid infiltrative disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Childhood diseases (eg, histiocytosis X and cystinosis) may involve the thyroid, with histiocytic infiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/42\">",
"     42",
"    </a>",
"    ] and cystine crystal deposition, respectively. These may result in goiter and, if severe enough, hypothyroidism. Children known to have these conditions should have periodic (annual) measurements of serum TSH. Histiocytosis X also can cause central hypothyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Goiter with hyperthyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a goiter with hyperthyroidism in children may be caused by Graves' disease or an autonomously functioning thyroid adenoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Graves' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Graves' disease with diffuse goiter and hyperthyroidism occurs in approximately 0.02 percent (1:5000) of children, mostly in adolescent girls. As in adults, the onset is usually insidious. As compared with adults, children with Graves' hyperthyroidism tend to have greater mood swings and disturbances of behavior, poorer attention span, and more disturbed sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/43\">",
"     43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Toxic adenoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autonomously functioning thyroid adenomas are rare causes of hyperthyroidism in children. These may present as a solitary nodule or with a toxic multinodular goiter. Some children have somatic mutations of the TSH receptor gene [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/44\">",
"     44",
"    </a>",
"    ], and others have mutations in the gene encoding the alpha subunit of the G protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thyroid cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid cysts are uncommon in children. Affected children typically present with a neck mass. The cysts are either so-called simple cysts or mixed solid and cystic nodules; the latter are usually the result of hemorrhagic degeneration of a thyroid adenoma.",
"   </p>",
"   <p>",
"    Ultrasonography should be performed to confirm that the mass is a thyroid cyst or a more complex mixed solid and cystic nodule. The cyst should be aspirated to obtain cells for cytological examination, and it may disappear if completely emptied. If the cytology is indeterminate or abnormal, surgical excision is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=see_link\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Thyroglossal duct cysts",
"    </span>",
"    &nbsp;&mdash;&nbsp;These are cysts of the thyroglossal duct or tract that form behind the thyroid as it moves from the base of the tongue inferiorly before dividing into the left and right thyroid lobes. Normally the duct is obliterated, but cysts can form within it. Most are located in the midline between the hyoid bone and the isthmus of the thyroid. A thyroglossal duct cyst may be present at birth; more often it appears during childhood or later [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Once detected, the cysts should be removed surgically. Most contain no thyroid cells, but a few do (thyroid ectopia). Very rarely, they are the patient's only thyroid tissue, so that the patient becomes hypothyroid after the 'cyst' is removed. A thyroid scan is recommended before surgery to determine if other thyroid tissue is present. Rarely, thyroid carcinomas arise in thyroglossal duct cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24280/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=see_link\">",
"     \"Thyroglossal duct cysts and ectopic thyroid\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=see_link\">",
"     \"Thyroid nodules and cancer in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal thyroid volume is approximately 1 mL at birth, and increases with age and body surface area. The \"rule of thumb\" can be used to evaluate thyroid size in older children: each lobe of the normal thyroid gland is approximately the size of the terminal phalanx of the child's thumb. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Thyroid size in infants and children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of congenital goiter include inborn errors of thyroid hormone production, transplacental passage of maternal antibodies, maternal ingestion of antithyroid drugs or goitrogens, activating mutations of the TSH receptor, and others (",
"      <a class=\"graphic graphic_table graphicRef71540 \" href=\"UTD.htm?19/4/19531\">",
"       table 2",
"      </a>",
"      ). Even in hereditary forms, the goiter and the thyroid dysfunction that often accompanies it may not be evident at birth. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Congenital goiter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of inborn errors of thyroid hormone production (dyshormonogenesis) have been described. All result in varying degrees of goiter and hypothyroidism, and may be detected by newborn screening. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Inborn errors of thyroid hormone production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with chronic autoimmune thyroiditis or Graves' disease may produce antibodies that cross the placenta, resulting in fetal and neonatal goiter and thyroid dysfunction, depending upon the type of antibody. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transplacental passage of maternal thyroid-reactive antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the United States and other iodine-sufficient areas of the world, the most common causes of acquired goiter are chronic autoimmune (Hashimoto's) thyroiditis and colloid goiter. Worldwide, iodine deficiency goiter is far more common. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Acquired goiter'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=see_link\">",
"       \"Iodine deficiency disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most children with autoimmune thyroiditis present with a firm, nontender goiter discovered incidentally by a parent or during a routine examination. Most of the children are euthyroid, but some have subclinical or overt hypothyroidism. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Chronic autoimmune (Hashimoto's) thyroiditis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colloid goiters are diffuse goiters, usually occurring in adolescent girls. They may be familial, but their cause is unknown. Thyroid function and serum antithyroid antibody concentrations are normal. These goiters usually gradually decrease in size over several years, without treatment. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Colloid goiter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children who present with a goiter and hyperthyroidism most likely have Graves' disease; less commonly they may have a toxic adenoma or toxic multinodular goiter. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link&amp;anchor=H17#H17\">",
"       \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\", section on 'Graves' disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid cysts are uncommon in children; they are typically discovered on examination and confirmed by ultrasonography, and may require further evaluation by fine-needle aspiration. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Thyroid cysts'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/1\">",
"      Vade A, Gottschalk ME, Yetter EM, Subbaiah P. Sonographic measurements of the neonatal thyroid gland. J Ultrasound Med 1997; 16:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/2\">",
"      Aghini-Lombardi F, Antonangeli L, Pinchera A, et al. Effect of iodized salt on thyroid volume of children living in an area previously characterized by moderate iodine deficiency. J Clin Endocrinol Metab 1997; 82:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/3\">",
"      Lisb&ouml;a HR, Gross JL, Orsolin A, Fuchs S. Clinical examination is not an accurate method of defining the presence of goitre in schoolchildren. Clin Endocrinol (Oxf) 1996; 45:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/4\">",
"      Fuse Y, Saito N, Tsuchiya T, et al. Smaller thyroid gland volume with high urinary iodine excretion in Japanese schoolchildren: normative reference values in an iodine-sufficient area and comparison with the WHO/ICCIDD reference. Thyroid 2007; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/5\">",
"      Muir A, Daneman D, Daneman A, Ehrlich R. Thyroid scanning, ultrasound, and serum thyroglobulin in determining the origin of congenital hypothyroidism. Am J Dis Child 1988; 142:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/6\">",
"      Pohlenz J, Rosenthal IM, Weiss RE, et al. Congenital hypothyroidism due to mutations in the sodium/iodide symporter. Identification of a nonsense mutation producing a downstream cryptic 3' splice site. J Clin Invest 1998; 101:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/7\">",
"      Nicola JP, Nazar M, Serrano-Nascimento C, et al. Iodide transport defect: functional characterization of a novel mutation in the Na+/I- symporter 5'-untranslated region in a patient with congenital hypothyroidism. J Clin Endocrinol Metab 2011; 96:E1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/8\">",
"      Spitzweg C, Morris JC. Genetics and phenomics of hypothyroidism and goiter due to NIS mutations. Mol Cell Endocrinol 2010; 322:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/9\">",
"      Ris-Stalpers C, Bikker H. Genetics and phenomics of hypothyroidism and goiter due to TPO mutations. Mol Cell Endocrinol 2010; 322:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/10\">",
"      De Marco G, Agretti P, Montanelli L, et al. Identification and functional analysis of novel dual oxidase 2 (DUOX2) mutations in children with congenital or subclinical hypothyroidism. J Clin Endocrinol Metab 2011; 96:E1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/11\">",
"      Kopp P, Bizhanova A. Clinical and molecular characteristics of Pendred syndrome. Ann Endocrinol (Paris) 2011; 72:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/12\">",
"      Scott DA, Wang R, Kreman TM, et al. The Pendred syndrome gene encodes a chloride-iodide transport protein. Nat Genet 1999; 21:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/13\">",
"      Everett LA, Morsli H, Wu DK, Green ED. Expression pattern of the mouse ortholog of the Pendred's syndrome gene (Pds) suggests a key role for pendrin in the inner ear. Proc Natl Acad Sci U S A 1999; 96:9727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/14\">",
"      van de Graaf SA, Ris-Stalpers C, Veenboer GJ, et al. A premature stopcodon in thyroglobulin messenger RNA results in familial goiter and moderate hypothyroidism. J Clin Endocrinol Metab 1999; 84:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/15\">",
"      Peteiro-Gonzalez D, Lee J, Rodriguez-Fontan J, et al. New insights into thyroglobulin pathophysiology revealed by the study of a family with congenital goiter. J Clin Endocrinol Metab 2010; 95:3522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/16\">",
"      Moreno JC, Klootwijk W, van Toor H, et al. Mutations in the iodotyrosine deiodinase gene and hypothyroidism. N Engl J Med 2008; 358:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/17\">",
"      Ribault V, Castanet M, Bertrand AM, et al. Experience with intraamniotic thyroxine treatment in nonimmune fetal goitrous hypothyroidism in 12 cases. J Clin Endocrinol Metab 2009; 94:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/18\">",
"      Brown RS, Bellisario RL, Mitchell E, et al. Detection of thyrotropin binding inhibitory activity in neonatal blood spots. J Clin Endocrinol Metab 1993; 77:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/19\">",
"      Thomas Jde V, Collett-Solberg PF. Perinatal goiter with increased iodine uptake and hypothyroidism due to excess maternal iodine ingestion. Horm Res 2009; 72:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/20\">",
"      Paschke R, Ludgate M. The thyrotropin receptor in thyroid diseases. N Engl J Med 1997; 337:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/21\">",
"      Ringel MD, Schwindinger WF, Levine MA. Clinical implications of genetic defects in G proteins. The molecular basis of McCune-Albright syndrome and Albright hereditary osteodystrophy. Medicine (Baltimore) 1996; 75:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/22\">",
"      Mastorakos G, Mitsiades NS, Doufas AG, Koutras DA. Hyperthyroidism in McCune-Albright syndrome with a review of thyroid abnormalities sixty years after the first report. Thyroid 1997; 7:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/23\">",
"      Maiorana R, Carta A, Floriddia G, et al. Thyroid hemiagenesis: prevalence in normal children and effect on thyroid function. J Clin Endocrinol Metab 2003; 88:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/24\">",
"      Rallison ML, Dobyns BM, Keating FR, et al. Occurrence and natural history of chronic lymphocytic thyroiditis in childhood. J Pediatr 1975; 86:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/25\">",
"      Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/26\">",
"      Popova G, Paterson WF, Brown A, Donaldson MD. Hashimoto's thyroiditis in Down's syndrome: clinical presentation and evolution. Horm Res 2008; 70:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/27\">",
"      de Vries L, Bulvik S, Phillip M. Chronic autoimmune thyroiditis in children and adolescents: at presentation and during long-term follow-up. Arch Dis Child 2009; 94:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/28\">",
"      Fava A, Oliverio R, Giuliano S, et al. Clinical evolution of autoimmune thyroiditis in children and adolescents. Thyroid 2009; 19:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/29\">",
"      Vlachopapadopoulou E, Thomas D, Karachaliou F, et al. Evolution of sonographic appearance of the thyroid gland in children with Hashimoto's thyroiditis. J Pediatr Endocrinol Metab 2009; 22:339.",
"     </a>",
"    </li>",
"    <li>",
"     Feinbold SB, Smith J, Houtz J, Popovsky E, Brown RS. Prevalence and functional significance of thyrotropin receptor blocking antibodies in children and adolescents with chronic lymphocytic thyroiditis. J Clin Endocrinol Metab 2009; Oct 22 [Epub ahead of print].",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/31\">",
"      Svensson J, Ericsson UB, Nilsson P, et al. Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis. J Clin Endocrinol Metab 2006; 91:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/32\">",
"      Scarpa V, Kousta E, Tertipi A, et al. Treatment with thyroxine reduces thyroid volume in euthyroid children and adolescents with chronic autoimmune thyroiditis. Horm Res Paediatr 2010; 73:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/33\">",
"      Corrias A, Cassio A, Weber G, et al. Thyroid nodules and cancer in children and adolescents affected by autoimmune thyroiditis. Arch Pediatr Adolesc Med 2008; 162:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/34\">",
"      Brix TH, Kyvik KO, Heged&uuml;s L. Major role of genes in the etiology of simple goiter in females: a population-based twin study. J Clin Endocrinol Metab 1999; 84:3071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/35\">",
"      Hollowell JG, Staehling NW, Hannon WH, et al. Iodine nutrition in the United States. Trends and public health implications: iodine excretion data from National Health and Nutrition Examination Surveys I and III (1971-1974 and 1988-1994). J Clin Endocrinol Metab 1998; 83:3401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/36\">",
"      Caldwell KL, Jones R, Hollowell JG. Urinary iodine concentration: United States National Health And Nutrition Examination Survey 2001-2002. Thyroid 2005; 15:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/37\">",
"      Zimmermann MB, Wegm&uuml;ller R, Zeder C, et al. The effects of vitamin A deficiency and vitamin A supplementation on thyroid function in goitrous children. J Clin Endocrinol Metab 2004; 89:5441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/38\">",
"      Erdoan MF, Demir O, Emral R, et al. More than a decade of iodine prophylaxis is needed to eradicate goiter among school age children in a moderately iodine-deficient region. Thyroid 2009; 19:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/39\">",
"      Boyages SC, Halpern JP, Maberly GF, et al. A comparative study of neurological and myxedematous endemic cretinism in western China. J Clin Endocrinol Metab 1988; 67:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/40\">",
"      Friedrich-Rust M, Theobald J, Zeuzem S, Bojunga J. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C. J Viral Hepat 2009; 16:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/41\">",
"      Shies A, Nemet D, Rathaus V, Eliakim A. Transient hyperthyroidism due to acute suppurative thyroiditis in an adolescent female. J Pediatr Endocrinol Metab 2011; 24:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/42\">",
"      Xia CX, Li R, Wang ZH, et al. A rare cause of goiter: Langerhans cell histiocytosis of the thyroid. Endocr J 2012; 59:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/43\">",
"      Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/44\">",
"      Schwab KO, Pfarr N, van der Werf-Grohmann N, et al. Autonomous thyroid adenoma: only an adulthood disease? J Pediatr 2009; 154:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/45\">",
"      Josephson GD, Spencer WR, Josephson JS. Thyroglossal duct cyst: the New York Eye and Ear Infirmary experience and a literature review. Ear Nose Throat J 1998; 77:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/46\">",
"      Ewing CA, Kornblut A, Greeley C, Manz H. Presentations of thyroglossal duct cysts in adults. Eur Arch Otorhinolaryngol 1999; 256:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24280/abstract/47\">",
"      Heshmati HM, Fatourechi V, van Heerden JA, et al. Thyroglossal duct carcinoma: report of 12 cases. Mayo Clin Proc 1997; 72:315.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5844 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-0E38AEEEDF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24280=[""].join("\n");
var outline_f23_45_24280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THYROID SIZE IN INFANTS AND CHILDREN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CONGENITAL GOITER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Inborn errors of thyroid hormone production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Transplacental passage of maternal thyroid-reactive antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Maternal ingestion of antithyroid drugs and other goitrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Activating mutations of the TSH-receptor (congenital nonimmune hyperthyroidism)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      McCune-Albright syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid hemiagenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACQUIRED GOITER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chronic autoimmune (Hashimoto's) thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25762082\">",
"      - Associations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25762089\">",
"      - Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25762096\">",
"      - Evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25762103\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Colloid goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Iodine-deficiency goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ingestion of goitrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Subacute granulomatous thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Acute suppurative thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Thyroid infiltrative disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Goiter with hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Toxic adenoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thyroid cysts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Thyroglossal duct cysts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5844\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5844|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/30/23019\" title=\"table 1\">",
"      Thyroid volume in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/4/19531\" title=\"table 2\">",
"      Causes of congenital goiter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/0/6156\" title=\"table 3\">",
"      Causes of acquired goiter in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39864?source=related_link\">",
"      Iodine deficiency disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1399?source=related_link\">",
"      Subacute thyroiditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10312?source=related_link\">",
"      Suppurative thyroiditis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/34/33320?source=related_link\">",
"      Thyroid hormone synthesis and physiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/41/23191?source=related_link\">",
"      Thyroid nodules and cancer in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24281="Adenocarcinoma colon Endosc";
var content_f23_45_24281=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F74346%7EGAST%2F54234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F74346%7EGAST%2F54234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1146px;\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Adenocarcinoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 183px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Adenocarcinoma of the colon may have a variety of appearances on endoscopy. Panel A: a typical exophytic mass; Panel B: a friable polypoid mass; Panel C: circumferential adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal sigmoid colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic appearance of the normal sigmoid colonic mucosa. The fine vasculature is easily visible, and the surface is shiny and smooth. The folds are of normal thickness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Necrotic adenocarcinoma of the colon",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 225px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy showing necrotic colonic lesions that usually suggest an advanced stage of malignancy. Panel A: severe tissue destruction has led to necrosis and bleeding; Panel B: the longstanding tumor has extended deeply into the mucosa and become necrotic.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24281=[""].join("\n");
var outline_f23_45_24281=null;
var title_f23_45_24282="Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma";
var content_f23_45_24282=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?23/45/24282/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?23/45/24282/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 25 percent of NHL cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is increasingly appreciated that the diagnostic category of \"DLBCL\" is quite heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized that are sufficiently distinct to be considered separate diagnostic categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T cell histiocyte rich large B cell lymphoma. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'T cell histiocyte rich large B cell lymphoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Primary DLBCL of the mediastinum, also called primary mediastinal large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravascular lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lymphomatoid granulomatosis, an Epstein-Barr virus positive large B cell lymphoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H763094\">",
"       'Lymphomatoid granulomatosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each of these is discussed separately in the sections that follow the general discussion of DLBCL, or in their own topics. In addition, the 2008 version of the World Health Organization (WHO) classification system provides two overlap categories termed [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma\". Some tumors in this group were previously classified as \"Burkitt-like\" lymphoma. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Burkitt lymphoma'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\". (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Hodgkin lymphoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, pathologic features, and diagnosis of DLBCL will be reviewed here. The pathobiology and treatment of this disorder are discussed separately, as is a general approach to the diagnosis, staging, and prognosis of the lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=see_link\">",
"     \"Initial treatment of limited stage diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DLBCL is the most common lymphoma and accounts for approximately 25 percent of all NHLs in the developed world&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States and England, the incidence of DLBCL is approximately 7 cases per 100,000 persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In Europe as a whole, the incidence is approximately 4.92 cases per 100,000 persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/4\">",
"     4",
"    </a>",
"    ]. Incidence varies by ethnicity, with Caucasian Americans having higher rates than Blacks, Asians, and American Indian or Alaska Natives, in order of decreasing incidence. By comparison, the incidence in Denmark is approximately 3 cases per 100,000 adults per year [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/5\">",
"     5",
"    </a>",
"    ]. DLBCL appears to be a more frequent subtype of NHL in Central and South America, where it accounts for approximately 40 percent of NHLs [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like most other NHLs, there is a male predominance with approximately 55 percent of cases occurring in men [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/2\">",
"     2",
"    </a>",
"    ]. Incidence increases with age; the median age at presentation is 64 years for patients as a whole, but appears to be younger for Blacks than for Caucasian Americans [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/7\">",
"     7",
"    </a>",
"    ]. Familial aggregation of patients with DLBCL and other NHL subtypes has been noted [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. As an example, a large population-based observational study of patients from Sweden and Denmark reported that relatives of probands with aggressive NHL had an approximately 3.5-fold increased risk of developing NHL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DLBCL arises from a mature B cell, and is usually comprised of cells resembling centroblasts or immunoblasts, two distinct types of activated B cells. The molecular pathogenesis of DLBCL is complex and includes both genetic lesions that are relatively specific for this disease (ie, rearrangements of BCL-6) and molecular alterations that are shared with other NHL variants. The pathogenesis of DLBCL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to occurring de novo, DLBCL can arise through the transformation of many different types of low grade B cell lymphomas, including B cell chronic lymphocytic leukemia (eg, Richter's transformation), lymphoplasmacytic lymphoma, follicular lymphoma, marginal zone (MALT) lymphoma, and splenic marginal zone lymphoma. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=see_link\">",
"     \"Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DLBCL is an AIDS-defining malignancy. The pathogenesis of NHL in the setting of HIV infection is poorly understood, but chronic B cell stimulation and T cell immunodeficiency leading to loss of control of transforming viruses, particularly Epstein-Barr virus (EBV), are thought to play important roles. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with DLBCL typically present with a rapidly enlarging symptomatic mass, most usually nodal enlargement in the neck or abdomen, or, in the case of primary mediastinal large B cell lymphoma, the mediastinum, but may present as a mass lesion anywhere in the body. When the presenting stage is limited, extranodal involvement is common [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/10\">",
"     10",
"    </a>",
"    ]. Systemic \"B\" symptoms (ie, fever, weight loss, drenching night sweats) are observed in approximately 30 percent of patients, and the serum lactate dehydrogenase (LDH) is elevated in over one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A more detailed discussion of systemic complaints seen in patients with NHL is presented separately, along with the specific definitions of B symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Systemic complaints (B symptoms)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approximately 60 percent of patients will present with advanced stage DLBCL (usually stage III or IV disease) while 40 percent have more localized disease, usually defined as that which can be contained within one irradiation field (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. The bone marrow is involved in up to 30 percent of cases, but may be of a discordant histologic type, such as follicular lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/13\">",
"     13",
"    </a>",
"    ], in as many as half of those cases. The staging of DLBCL is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extranodal extramedullary disease occurs in up to 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/5\">",
"     5",
"    </a>",
"    ]. The most common site of extranodal involvement is the",
"    <span class=\"nowrap\">",
"     stomach/gastrointestinal",
"    </span>",
"    tract (",
"    <a class=\"graphic graphic_picture graphicRef51705 \" href=\"UTD.htm?33/45/34512\">",
"     picture 1",
"    </a>",
"    ), but the disease can arise in virtually any tissue, including the testis, bone, thyroid, salivary glands, tonsil, skin, liver, breast, adrenals, kidneys, nasal cavity, paranasal sinuses, uterine cervix, vagina and central nervous system [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/14-35\">",
"     14-35",
"    </a>",
"    ]. Many of these presentations are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"       \"Primary cutaneous large B cell lymphoma, leg type\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lung (see",
"      <a class=\"local\" href=\"#H763094\">",
"       'Lymphomatoid granulomatosis'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bone (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32599?source=see_link\">",
"       \"Primary lymphoma of bone\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thyroid (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=see_link\">",
"       \"Thyroid lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal tract (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mediastinum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central nervous system (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Breast (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"       \"Breast lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Testis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H30#H30\">",
"       \"Anatomy and pathology of testicular tumors\", section on 'Testicular lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heart (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=see_link\">",
"       \"Cardiac tumors\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the course of the disease, the liver, kidneys, lung, bone marrow, and central nervous system may become involved. DLBCL can be highly invasive, with local compression of vessels (eg, superior vena cava syndrome) or airways (eg, tracheo-bronchial compression), involvement of peripheral nerves, and destruction of bone (eg, cord compression), requiring urgent attention. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=see_link\">",
"     \"Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DLBCL is an AIDS-defining malignancy. When compared with lymphoma in the HIV-negative population, systemic lymphoma in the HIV-positive population is characterized by more frequent B symptoms (ie, fever, weight loss, night sweats), extranodal disease, involvement of unusual locations (eg, body cavity, rectum, soft tissue), and advanced stage at diagnosis. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high (&gt;40 percent) proliferation fraction (",
"    <a class=\"graphic graphic_picture graphicRef81533 \" href=\"UTD.htm?2/7/2165\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1386915\">",
"    <span class=\"h3\">",
"     Typical morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymph nodes usually demonstrate complete effacement of the normal architecture by sheets of atypical lymphoid cells. The tumor cells are of large size (eg, nuclei at least twice the size of a small lymphocyte and larger than the nucleus of a tissue macrophage) and often resemble normal centroblasts or immunoblasts (",
"    <a class=\"graphic graphic_picture graphicRef67243 \" href=\"UTD.htm?16/32/16903\">",
"     picture 3",
"    </a>",
"    ). Centroblasts are large, noncleaved cells with round or oval nuclei, vesicular chromatin, often multiple peripheral nucleoli and a narrow rim of basophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef82926 \" href=\"UTD.htm?24/43/25270\">",
"     picture 4",
"    </a>",
"    ). Immunoblasts are larger cells with very prominent nucleoli and abundant cytoplasm, often with plasmacytoid features (",
"    <a class=\"graphic graphic_picture graphicRef82925 \" href=\"UTD.htm?36/57/37783\">",
"     picture 5",
"    </a>",
"    ). Some tumors contain mixtures of centroblastic and immunoblastic forms.",
"   </p>",
"   <p>",
"    In addition to the common centroblastic and immunoblastic morphologies, several other cytologic variants are recognized (eg, multilobated and anaplastic), but their clinical significance is debated [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/36\">",
"     36",
"    </a>",
"    ]. In addition, there is poor intra- and interobserver reproducibility among hematopathologists attempting to subtype DLBCL based on the appearance of the tumor cells, and as a result the morphologic subtypes of DLBCL are lumped together in a single diagnostic category in the current WHO classification of lymphoid neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1\">",
"     1",
"    </a>",
"    ]. In contrast, plasmablastic lymphoma is a morphologic variant that displays immunophenotypic characteristics that allow for its distinction from other DLBCLs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1386908\">",
"    <span class=\"h3\">",
"     Plasmablastic lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tumor cells of plasmablastic lymphoma typically have large, eccentrically placed nuclei, often with prominent single nucleoli, and abundant basophilic cytoplasm, which together constitute a \"plasmablast-like\" appearance. Unlike the other morphologic variants described above, plasmablastic tumors are immunophenotypically distinct. Specifically, these tumors are comprised of late B cells that express plasma cell markers (eg, CD 138) instead of the pan-B cell markers found in typical DLBCL (eg, CD20 and CD79a). Some tumors belonging to this group have distinctive genetic or clinicopathologic features. For example, oropharyngeal plasmablastic lymphomas occur most frequently in HIV-positive individuals and are often positive for Epstein-Barr virus. Another rare genetic subtype of plasmablastic lymphoma has rearrangements of the ALK tyrosine kinase gene, discussed in more detail below. Because of the plasmacellular differentiation of these tumors, they can be easily mistaken for anaplastic myeloma when they involve the bone marrow. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Other mutations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunophenotype of DLBCL can be confirmed by histochemistry or flow cytometry (",
"    <a class=\"graphic graphic_figure graphicRef77348 \" href=\"UTD.htm?30/49/31508\">",
"     figure 1",
"    </a>",
"    ). Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a), as well as CD45 (",
"    <a class=\"graphic graphic_picture graphicRef74703 \" href=\"UTD.htm?41/39/42614\">",
"     picture 6",
"    </a>",
"    ). Fifty to 75 percent of tumors express surface or cytoplasmic monoclonal immunoglobulin (Ig), most often of the IgM isotype. The immunoglobulin variable region genes have undergone rearrangement and are commonly somatically mutated; clonally related subpopulations may express alternative isotypes (isotype switch variants) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/37\">",
"     37",
"    </a>",
"    ]. Uncommonly, DLBCLs express CD30 (particularly the anaplastic variant) or CD5 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. Analysis of 109 patients with CD5-expressing DLBCL indicated that tumors that express CD5 are more aggressive than CD5 negative DLBCL, with a significantly worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twenty-five to 80 percent of DLBCL in various studies express B cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    2 (BCL-2) protein (",
"    <a class=\"graphic graphic_picture graphicRef65528 \" href=\"UTD.htm?7/29/7640\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/42-47\">",
"     42-47",
"    </a>",
"    ]. Approximately 70 percent express B cell lymphoma 6 (BCL-6) protein; this expression is independent of BCL-6 gene rearrangement (",
"    <a class=\"graphic graphic_picture graphicRef53759 \" href=\"UTD.htm?0/11/182\">",
"     picture 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Other markers that are commonly expressed include CD10 (30 to 60 percent of cases) and",
"    <span class=\"nowrap\">",
"     MUM1/IRF4",
"    </span>",
"    (35 to 65 percent of cases). Although",
"    <span class=\"nowrap\">",
"     MUM1/IRF4",
"    </span>",
"    and BCL-6 are not co-expressed in normal B cells, co-expression of both markers is found in up to 50 percent of DLBCLs. The proliferative fraction of cells, as determined by Ki-67 staining, is usually higher than 40 percent, and may occasionally be &gt;90 percent, which may make distinguishing DLBCL from Burkitt lymphoma difficult in some cases (",
"    <a class=\"graphic graphic_picture graphicRef77463 \" href=\"UTD.htm?0/44/714\">",
"     picture 9",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Aberrant BCL-6 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of DLBCL tumors have genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. Most tumors demonstrate rearrangement of the immunoglobulin gene heavy and light chains and somatic mutations of the variable regions [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Alterations in BCL-6",
"    </span>",
"    &nbsp;&mdash;&nbsp;The B cell lymphoma 6 (BCL-6) gene located on chromosome 3 is rearranged in 20 to 40 percent of cases and shows mutations in the 5' noncoding region in 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. Over 20 different translocations involving BCL-6 have been identified. Both 5' noncoding mutations of the BCL-6 proto-oncogene and immunoglobulin variable region gene mutations are found in normal germinal center cells [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]; their presence in DLBCL is consistent with a germinal center or post-germinal center stage of differentiation. The 5' noncoding mutations abolish negative auto-regulation of expression by BCL-6, which is a transcriptional repressor, whereas the translocations replace the BCL-6 promoter with strong, constitutively active promoters derived from many different genes. The net effect of both the mutations and translocations is the same: the inappropriate over-expression of BCL-6. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H3#H3\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'Aberrant BCL-6 expression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     (14;18) translocation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The t(14;18) seen in &gt;90 percent of cases of follicular lymphomas is also present in approximately 30 percent of patients with DLBCL. Such cases might represent histologic transformations of a prior follicular lymphoma, or be associated with the DLBCL subset demonstrating a germinal center B cell gene expression profile [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. In cases of histologic transformation, mutations of p53 are observed at a high frequency, as well as homozygous deletions at 9p21, which involve p15 and p16 tumor suppressors [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/60-63\">",
"     60-63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=see_link&amp;anchor=H27#H27\">",
"     \"Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma\", section on 'Histologic transformation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma\", section on 'p53 mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The t(14;18) is associated with nodal and disseminated disease, but is not associated with either a worse prognosis or with BCL-2 expression, which is observed in many tumors without the t(14;18) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/42,64\">",
"     42,64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other abnormalities have been reported in DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A comprehensive analysis of 363 cases of DLBCL found clonal karyotypic abnormalities in 87 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. The most common sites involved were 14q32, 18q21, 1q21, 3q27, 1q36, 8q24, 3p21, 6q21, 1p22, and 22q11. Immunoglobulin genes were clonally rearranged.",
"     </li>",
"     <li>",
"      The c-MYC gene (ie, 8q24) is rearranged in 5 to 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/51,68,69\">",
"       51,68,69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rare plasmablastic forms of DLBCL have a (2;17)(p23;q23) translocation involving ALK and the clathrin gene (CLTC) [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/70,71\">",
"       70,71",
"      </a>",
"      ]. These are late B cell tumors that are usually negative for CD20, CD79a, and CD30, positive for plasma cell markers such as CD138, and show granular cytoplasmic staining for ALK. Some series indicate a male predominance and a poor prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/72,73\">",
"       72,73",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1386908\">",
"       'Plasmablastic lymphoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deep sequencing of DLBCL genomes has identified over 400 different loci involved by tumor-specific somatic point mutations or recurrent copy number alterations [",
"      <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/74-76\">",
"       74-76",
"      </a>",
"      ], with most tumors harboring &gt;100 mutations in coding sequences (exons) alone. Of note, a number of the most frequently mutated genes encode enzymes that modify histones, including the histone acetyltransferases P300 and CREBP and the histone methyltransferase MLL2, suggesting that epigenetic changes in DLBCL cells are likely to have a central pathogenic role in these tumors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8316507\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of DLBCL is best made based by excisional tissue biopsy, most commonly a lymph node. While an excisional lymph node biopsy is the preferred diagnostic test for most patients, some patients do not present with overt lymphadenopathy and require the pathologic evaluation of another tissue (ie, pleural fluid, spleen) for diagnosis. A discussion of lymph node and tissue biopsy including the selection of a lymph node to biopsy is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\", section on 'Lymph node and tissue biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8316514\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic diagnosis of DLBCL is based on morphology and immunophenotyping, which is essential to make the diagnosis. Staining for pan-B cell markers, such as CD20 and CD79a, is sufficient to establish the diagnosis in many cases, but a much broader set of stains may be needed in cases with atypical morphologic features. In rare cases with plasmablastic features, correlation with other clinical and laboratory features may be necessary to distinguish the tumor from multiple myeloma.",
"   </p>",
"   <p>",
"    As described in more detail above, DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation fraction. Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a). The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. Tumors are not routinely subtyped based on underlying genetic abnormalities, but this is an area of ongoing research.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of DLBCL includes other entities that can result in lymphadenopathy and similar pathologic features. These include infectious mononucleosis and large cell malignancies such as carcinoma, melanoma, and other types of lymphoma (",
"    <a class=\"graphic graphic_table graphicRef56467 \" href=\"UTD.htm?17/2/17452\">",
"     table 2",
"    </a>",
"    ). These are described in more detail below.",
"   </p>",
"   <p>",
"    The differential diagnosis of patients presenting with primary extranodal involvement depends upon the presenting symptoms. Many of these extranodal presentations are described in more detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=see_link\">",
"       \"Primary cutaneous large B cell lymphoma, leg type\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lung (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"       \"Pulmonary lymphomatoid granulomatosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Bone (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32599?source=see_link\">",
"       \"Primary lymphoma of bone\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thyroid (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=see_link\">",
"       \"Thyroid lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gastrointestinal tract (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=see_link\">",
"       \"Clinical presentation and diagnosis of primary gastrointestinal lymphomas\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Mediastinum (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Central nervous system (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=see_link\">",
"       \"Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Breast (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"       \"Breast lymphoma\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Testis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H30#H30\">",
"       \"Anatomy and pathology of testicular tumors\", section on 'Testicular lymphoma'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Intravascular lymphoma (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"       \"Intravascular large cell lymphoma\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1202993\">",
"    <span class=\"h2\">",
"     Infectious mononucleosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both infectious mononucleosis and the immunoblastic variant of DLBCL have prominent immunoblasts and Hodgkin-like cells on lymph node biopsy. However, T cells predominate in infectious mononucleosis, while B cells predominate in DLBCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=see_link\">",
"     \"Infectious mononucleosis in adults and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Morphologically, lymph node involvement with carcinoma may resemble DLBCL in that both tumors are comprised of large atypical cells. Carcinoma can be readily distinguished from DLBCL by the demonstration of cytokeratins by immunohistochemistry upon staining.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both melanoma and DLBCL have large atypical cells and can involve lymph nodes. However, unlike DLBCL, melanoma is positive for S100, HMB-45,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Melan A. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=see_link\">",
"     \"Pathologic characteristics of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17218494\">",
"    <span class=\"h2\">",
"     Gray zone lymphoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Burkitt lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differentiation between DLBCL and Burkitt lymphoma (BL) can be difficult since DLBCL can have high proliferation fractions and cytogenetic abnormalities, such as t(8;14), typically seen in BL.",
"   </p>",
"   <p>",
"    The 2008 version of the WHO classification system provides an overlap category termed \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and BL\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1\">",
"     1",
"    </a>",
"    ]. Some tumors in this group were previously classified as \"Burkitt-like\" lymphoma. The category is not homogeneous, but encompasses several types of aggressive B lymphoma that are difficult to place into the BL or DLBCL categories. These include lymphomas comprised of a mixture of large cells resembling DLBCL and smaller cells resembling BL, and tumors that more closely resemble BL morphologically but have atypical immunophenotypic or genetic features. c-MYC rearrangements may be present, but these are often complex (instead of the simple translocations associated with BL) and sometimes associated with other genetic aberrations that are not seen in BL, such as the t(14;18) (eg, &ldquo;double hit lymphomas&rdquo;) or rearrangements involving BCL-6 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/77\">",
"     77",
"    </a>",
"    ]. This category does not include tumors that have typical DLBCL morphology but demonstrate the c-MYC rearrangement. Based on expression profiling data that suggest that up to 5 percent of otherwise typical BL lack c-MYC rearrangements, it is also acceptable to make a diagnosis of BL in tumors that lack a detectable c-MYC rearrangement, but are typical of BL in all other respects [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features that favor the diagnosis of DLBCL include the presence of additional cytogenetic abnormalities, such as BCL-6 gene rearrangements or t(14;18); Ki-67 staining in less than 95 percent of the tumor cells; and positivity for BCL-2 (which is present in most DLBCLs and usually absent from Burkitt lymphoma). Gene expression profiling also shows promise in enhancing current pathologic methods for distinguishing DLBCL from Burkitt lymphoma, but is not yet available clinically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\", section on 'Diffuse large B cell lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases of the T cell histiocyte rich large B cell variant may resemble Hodgkin lymphoma of either the lymphocyte predominant or lymphocyte rich classical types [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/81-84\">",
"     81-84",
"    </a>",
"    ]. Lymphocyte predominant Hodgkin lymphoma (LPHL) usually has a nodular growth pattern and presents with low-stage disease, in contrast to T",
"    <span class=\"nowrap\">",
"     cell/histiocyte-rich",
"    </span>",
"    large B cell lymphoma, which grows in a diffuse pattern and typically presents with disseminated disease involving the liver and spleen. However, the distinction between unusual cases of advanced stage LPHL and T cell histiocyte rich large B cell can be very difficult, as the tumor cells in these two disorders have similar immunophenotypes. The lymphocyte rich subtype of classical Hodgkin lymphoma is usually more easily distinguished by expression of markers that are specific for classical forms of Hodgkin lymphoma, such as CD15 and CD30, and the presence of EBV, which can be detected in 40 percent of lymphocyte rich classical Hodgkin lymphoma, but is not associated with T cell histiocyte rich large B cell lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"     \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 2008 version of the WHO classification system provides an overlap category termed \"B cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical Hodgkin lymphoma\" [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1\">",
"     1",
"    </a>",
"    ]. This category includes tumors that morphologically resemble classical Hodgkin lymphoma, but have immunophenotypes more typical of DLBCL. A potentially related issue is the occurrence of composite tumors containing areas of classical Hodgkin lymphoma and areas of DLBCL and the sequential occurrence of both of these tumor types in the same patient at different points in time. This situation arises most often in patients with primary mediastinal large B cell lymphoma, which shares certain genetic and immunophenotypic features with classical Hodgkin lymphoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17218451\">",
"    <span class=\"h2\">",
"     Anaplastic large cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of the anaplastic variant of DLBCL are morphologically identical to those of anaplastic large cell lymphoma",
"    <span class=\"nowrap\">",
"     T/null-cell",
"    </span>",
"    type and strongly express CD30 (Ki-1). The key diagnostic criterion for such cases is the expression of B cell antigens, which are absent in ALCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14074238\">",
"    <span class=\"h2\">",
"     Histologic transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of patients with pathologic findings consistent with DLBCL will have had a previously undiagnosed indolent lymphoma (eg, follicular lymphoma) that has undergone histologic transformation. Such patients may have a history of waxing and waning lymphadenopathy, with a more recent rapid progression of lymphadenopathy, infiltration of extranodal sites, development of systemic symptoms,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated serum lactate dehydrogenase (LDH).",
"   </p>",
"   <p>",
"    Histology can vary greatly in different sections of the same lymph node. As such, careful examination of the sampled lymph node is key to determining whether a component of DLBCL is present. Discordant histologic features suggest histologic transformation of a previously undiagnosed indolent lymphoma. As an example, a small B cell proliferation may be identified in the bone marrow in a patient with large B cell involvement in a lymph node. The detection of areas of DLBCL within the lymph node denotes transformation to an aggressive phase of disease. This subject is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=see_link\">",
"     \"Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DISTINCTIVE CLINICOPATHOLOGIC SUBTYPES OF DLBCL",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     T cell histiocyte rich large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;All cases of DLBCL have some infiltrating reactive T cells and macrophages (histiocytes), but in some tumors these cells predominate. This is the so-called T cell or histiocyte-rich large B cell lymphoma (",
"    <a class=\"graphic graphic_picture graphicRef76125 \" href=\"UTD.htm?2/44/2761\">",
"     picture 10",
"    </a>",
"    ). Some experts have suggested that less than 10 percent of the cellularity should be comprised of tumor cells for this diagnosis to be made.",
"   </p>",
"   <p>",
"    In one study of 40 patients with this variant, the median age was 49 years (range: 21 to 87), with a male to female ratio of 2.6:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/85\">",
"     85",
"    </a>",
"    ]. Splenomegaly, bone marrow involvement, and hepatomegaly were present in 60, 43, and 40 percent, respectively. The International Prognostic Index (IPI) (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"UTD.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ) was &ge;2 in 77 percent of the patients. Neoplastic cells were uniformly positive for CD20 and negative for CD5, CD10, CD15, and CD138. Despite their relatively young age and the use of combination chemotherapy, complete remissions were attained in only 40 percent, with an overall survival of 50 percent at three years. On multivariate analysis, only the IPI and loss-of-function mutations (eg, deletions or point mutations) in p53 were predictive of failure-free survival.",
"   </p>",
"   <p>",
"    In a separate study, there was no difference in five-year overall survival or event-free survival between this variant and DLBCL when subjects were matched for the prognostic features comprising the IPI [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Primary mediastinal large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary large B cell lymphoma of the mediastinum is a distinct clinicopathologic entity that arises from the thymic (medullary) B cell. It has clinical and pathologic features that differ from DLBCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Intravascular large B cell lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cases of large cell lymphoma, almost always of B cell type, occasionally of T cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/87\">",
"     87",
"    </a>",
"    ], and even less commonly of NK-cell origin, present with a disseminated intravascular proliferation of large lymphoid cells, involving small blood vessels, without an obvious extravascular tumor mass or leukemia (",
"    <a class=\"graphic graphic_picture graphicRef62103 \" href=\"UTD.htm?4/41/4757\">",
"     picture 11",
"    </a>",
"    ). This tumor has been variously known as intravascular lymphomatosis, angiotropic large cell lymphoma, and malignant angioendotheliomatosis. The organs most commonly affected are central nervous system, kidneys, lungs, and skin, but virtually any site may be involved. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=see_link\">",
"     \"Intravascular large cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H763094\">",
"    <span class=\"h2\">",
"     Lymphomatoid granulomatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphomatoid granulomatosis is an Epstein-Barr virus-positive large B cell lymphoma with a T cell-rich background that is clinically and pathologically distinct from DLBCL [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1,88\">",
"     1,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with lymphomatoid granulomatosis typically present with cough (60 percent), fever (60 percent),",
"    <span class=\"nowrap\">",
"     rash/nodules",
"    </span>",
"    (40 percent), malaise (35 percent), weight loss (35 percent), neurological abnormalities (30 percent), dyspnea (30 percent), or chest pain (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/89\">",
"     89",
"    </a>",
"    ]. Extranodal disease is common. Most patients have lung involvement at some point during their clinical course. Other commonly involved sites include kidney, liver, brain, and skin. Lymph nodes and spleen are very rarely involved. Evidence of past or present immunodeficiency may be found.",
"   </p>",
"   <p>",
"    On histology, the infiltrates show extensive necrosis, often with only a few atypical large B cells in a pleomorphic background of lymphocytes, plasma cells, and histiocytes; the infiltrate may be both angiocentric and angioinvasive. The large atypical B cells, when present, represent the neoplastic component and show evidence of Epstein-Barr virus infection with in situ hybridization. Pulmonary nodules may exhibit central necrosis and cavitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=see_link\">",
"     \"Pulmonary lymphomatoid granulomatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the infiltrates may resemble those of",
"    <span class=\"nowrap\">",
"     nasal/angiocentric",
"    </span>",
"    lymphoma, there is no biological and little clinical overlap, since the latter is an NK cell or T cell neoplasm that involves the upper airway and midfacial region, skin, and sometimes the gastrointestinal tract, and rarely the lung or central nervous system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2612844\">",
"    <span class=\"h2\">",
"     EBV-positive DLBCL of the elderly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epstein-Barr virus (EBV)-positive DLBCL of the elderly is considered a provisional entity in the 2008 WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/1\">",
"     1",
"    </a>",
"    ]. This is a clonal B cell lymphoproliferative disorder seen in patients &gt;50 years old without known immunodeficiency or prior lymphoma. This entity is seen most commonly in Asian countries where it accounts for 8 to 10 percent of DLBCL among patients without a known immunodeficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?23/45/24282/abstract/90-92\">",
"     90-92",
"    </a>",
"    ]. The majority of patients present with extranodal disease, with or without nodal involvement. This entity may overlap with lymphomatoid granulomatosis (described above), differing mainly in the prevalence of EBV-positive B cells in the involved tissues (ie, few in lymphomatoid granulomatosis, many in EBV-positive DLBCL of the elderly). (See",
"    <a class=\"local\" href=\"#H763094\">",
"     'Lymphomatoid granulomatosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=see_link\">",
"       \"Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diffuse large B cell lymphoma (DLBCL) is the most common histologic subtype of non-Hodgkin lymphoma (NHL) accounting for approximately 25 percent of NHL cases. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with DLBCL typically present with a rapidly enlarging symptomatic mass, most usually nodal enlargement in the neck or abdomen. Systemic \"B\" symptoms (ie, fever, weight loss, drenching night sweats) are observed in approximately 30 percent of patients. Bone marrow involvement and extranodal extramedullary disease are seen in up to 30 and 40 percent of cases, respectively. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      DLBCL is a heterogeneous group of tumors consisting of large, transformed B cells with prominent nucleoli and basophilic cytoplasm, a diffuse growth pattern and a high proliferation fraction (",
"      <a class=\"graphic graphic_picture graphicRef81533 \" href=\"UTD.htm?2/7/2165\">",
"       picture 2",
"      </a>",
"      ). Tumor cells in DLBCL generally express pan B cell antigens (CD19, CD20, CD22, CD79a). The majority has genetic abnormalities, but there is no single cytogenetic change that is typical or diagnostic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DLBCL is best made based by excisional tissue biopsy, most commonly a lymph node. The diagnosis is based on morphology and immunophenotyping, which is essential to make the diagnosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of DLBCL includes other large cell malignancies, such as carcinoma, melanoma, and other types of lymphoma (",
"      <a class=\"graphic graphic_table graphicRef56467 \" href=\"UTD.htm?17/2/17452\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is increasingly appreciated that the diagnostic category of \"DLBCL\" is quite heterogeneous in terms of morphology, genetics, and biologic behavior. A number of clinicopathologic entities are now recognized that are sufficiently distinct to be considered separate diagnostic categories:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      T cell rich large B cell lymphoma (see",
"      <a class=\"local\" href=\"#H21\">",
"       'T cell histiocyte rich large B cell lymphoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Primary mediastinal large B cell lymphoma (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Primary mediastinal large B cell lymphoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Intravascular lymphoma (see",
"      <a class=\"local\" href=\"#H23\">",
"       'Intravascular large B cell lymphoma'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Lymphomatoid granulomatosis and EBV-positive DLBCL of the elderly (see",
"      <a class=\"local\" href=\"#H763094\">",
"       'Lymphomatoid granulomatosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2612844\">",
"       'EBV-positive DLBCL of the elderly'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/2\">",
"      Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006; 107:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/3\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/4\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/5\">",
"      M&oslash;ller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. Br J Haematol 2004; 124:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/6\">",
"      Laurini JA, Perry AM, Boilesen E, et al. Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. Blood 2012; 120:4795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/7\">",
"      Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/8\">",
"      Goldin LR, Landgren O, McMaster ML, et al. Familial aggregation and heterogeneity of non-Hodgkin lymphoma in population-based samples. Cancer Epidemiol Biomarkers Prev 2005; 14:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/9\">",
"      Goldin LR, Bj&ouml;rkholm M, Kristinsson SY, et al. Highly increased familial risks for specific lymphoma subtypes. Br J Haematol 2009; 146:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/10\">",
"      Hui D, Proctor B, Donaldson J, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma 2010; 51:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/11\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/12\">",
"      A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/13\">",
"      Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/14\">",
"      Avil&eacute;s A, Neri N, Huerta-Guzm&aacute;n J. Large bowel lymphoma: an analysis of prognostic factors and therapy in 53 patients. J Surg Oncol 2002; 80:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/15\">",
"      Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma. J Clin Oncol 2003; 21:2740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/16\">",
"      Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years? Br J Haematol 2007; 136:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/17\">",
"      Seymour JF, Solomon B, Wolf MM, et al. Primary large-cell non-Hodgkin's lymphoma of the testis: a retrospective analysis of patterns of failure and prognostic factors. Clin Lymphoma 2001; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/18\">",
"      Vitolo U, Ferreri AJ, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol 2008; 65:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/19\">",
"      Olivier KR, Brown PD, Stafford SL, et al. Efficacy and treatment-related toxicity of radiotherapy for early-stage primary non-Hodgkin lymphoma of the parotid gland. Int J Radiat Oncol Biol Phys 2004; 60:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/20\">",
"      Laskar S, Bahl G, Muckaden MA, et al. Primary diffuse large B-cell lymphoma of the tonsil: is a higher radiotherapy dose required? Cancer 2007; 110:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/21\">",
"      Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol 2001; 19:3602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/22\">",
"      Page RD, Romaguera JE, Osborne B, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer 2001; 92:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/23\">",
"      Ribrag V, Bibeau F, El Weshi A, et al. Primary breast lymphoma: a report of 20 cases. Br J Haematol 2001; 115:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/24\">",
"      Domchek SM, Hecht JL, Fleming MD, et al. Lymphomas of the breast: primary and secondary involvement. Cancer 2002; 94:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/25\">",
"      Avil&eacute;s A, Delgado S, Nambo MJ, et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/26\">",
"      Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma 2003; 4:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/27\">",
"      Shikama N, Ikeda H, Nakamura S, et al. Localized aggressive non-Hodgkin's lymphoma of the nasal cavity: a survey by the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 2001; 51:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/28\">",
"      Proulx GM, Caudra-Garcia I, Ferry J, et al. Lymphoma of the nasal cavity and paranasal sinuses: treatment and outcome of early-stage disease. Am J Clin Oncol 2003; 26:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/29\">",
"      Oprea C, Cainap C, Azoulay R, et al. Primary diffuse large B-cell non-Hodgkin lymphoma of the paranasal sinuses: a report of 14 cases. Br J Haematol 2005; 131:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/30\">",
"      Dursun P, Gultekin M, Bozdag G, et al. Primary cervical lymphoma: report of two cases and review of the literature. Gynecol Oncol 2005; 98:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/31\">",
"      Monnard V, Sun A, Epelbaum R, et al. Primary spinal epidural lymphoma: patients' profile, outcome, and prognostic factors: a multicenter Rare Cancer Network study. Int J Radiat Oncol Biol Phys 2006; 65:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/32\">",
"      Kuo CC, Li WY, Huang CC, et al. Primary renal lymphoma. Br J Haematol 2009; 144:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/33\">",
"      Lu NN, Li YX, Wang WH, et al. Clinical behavior and treatment outcome of primary nasal diffuse large B-cell lymphoma. Cancer 2012; 118:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/34\">",
"      Guastafierro S, Tedeschi A, Criscuolo C, et al. Primary extranodal non-Hodgkin's lymphoma of the vagina: a case report and a review of the literature. Acta Haematol 2012; 128:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/35\">",
"      de Leval L, Bonnet C, Copie-Bergman C, et al. Diffuse large B-cell lymphoma of Waldeyer's ring has distinct clinicopathologic features: a GELA study. Ann Oncol 2012; 23:3143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/36\">",
"      De Paepe P, Achten R, Verhoef G, et al. Large cleaved and immunoblastic lymphoma may represent two distinct clinicopathologic entities within the group of diffuse large B-cell lymphomas. J Clin Oncol 2005; 23:7060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/37\">",
"      Ottensmeier CH, Stevenson FK. Isotype switch variants reveal clonally related subpopulations in diffuse large B-cell lymphoma. Blood 2000; 96:2550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/38\">",
"      Stein H, Lennert K, Feller AC, Mason DY. Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984; 42:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/39\">",
"      Doggett RS, Wood GS, Horning S, et al. The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 1984; 115:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/40\">",
"      Katzenberger T, Lohr A, Schwarz S, et al. Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. Blood 2003; 101:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/41\">",
"      Yamaguchi M, Seto M, Okamoto M, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 2002; 99:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/42\">",
"      Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997; 90:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/43\">",
"      Kramer MH, Hermans J, Parker J, et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/44\">",
"      Sanchez E, Chacon I, Plaza MM, et al. Clinical outcome in diffuse large B-cell lymphoma is dependent on the relationship between different cell-cycle regulator proteins. J Clin Oncol 1998; 16:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/45\">",
"      Skinnider BF, Horsman DE, Dupuis B, Gascoyne RD. Bcl-6 and Bcl-2 protein expression in diffuse large B-cell lymphoma and follicular lymphoma: correlation with 3q27 and 18q21 chromosomal abnormalities. Hum Pathol 1999; 30:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/46\">",
"      de Leval L, Ferry JA, Falini B, et al. Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells? Am J Surg Pathol 2001; 25:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/47\">",
"      Colomo L, L&oacute;pez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood 2003; 101:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/48\">",
"      Klein U, Goossens T, Fischer M, et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/49\">",
"      K&uuml;ppers R, Rajewsky K, Hansmann ML. Diffuse large cell lymphomas are derived from mature B cells carrying V region genes with a high load of somatic mutation and evidence of selection for antibody expression. Eur J Immunol 1997; 27:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/50\">",
"      Bastard C, Deweindt C, Kerckaert JP, et al. LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients. Blood 1994; 83:2423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/51\">",
"      Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92:3152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/52\">",
"      Barrans SL, O'Connor SJ, Evans PA, et al. Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 2002; 117:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/53\">",
"      Migliazza A, Martinotti S, Chen W, et al. Frequent somatic hypermutation of the 5' noncoding region of the BCL6 gene in B-cell lymphoma. Proc Natl Acad Sci U S A 1995; 92:12520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/54\">",
"      Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol 1998; 9:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/55\">",
"      Peng HZ, Du MQ, Koulis A, et al. Nonimmunoglobulin gene hypermutation in germinal center B cells. Blood 1999; 93:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/56\">",
"      Shen HM, Peters A, Baron B, et al. Mutation of BCL-6 gene in normal B cells by the process of somatic hypermutation of Ig genes. Science 1998; 280:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/57\">",
"      K&uuml;ppers R, Zhao M, Hansmann ML, Rajewsky K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J 1993; 12:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/58\">",
"      Huang JZ, Sanger WG, Greiner TC, et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/59\">",
"      Barrans SL, Evans PA, O'Connor SJ, et al. The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 2003; 9:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/60\">",
"      Tagawa H, Suguro M, Tsuzuki S, et al. Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma. Blood 2005; 106:1770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/61\">",
"      Lo Coco F, Gaidano G, Louie DC, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/62\">",
"      Elenitoba-Johnson KS, Gascoyne RD, Lim MS, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91:4677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/63\">",
"      Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88:3937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/64\">",
"      Papakonstantinou G, Verbeke C, Hastka J, et al. bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl-2 gene rearrangements. Br J Haematol 2001; 113:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/65\">",
"      Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplification in diffuse large B-cell lymphoma. Blood 1998; 92:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/66\">",
"      Cigudosa JC, Parsa NZ, Louie DC, et al. Cytogenetic analysis of 363 consecutively ascertained diffuse large B-cell lymphomas. Genes Chromosomes Cancer 1999; 25:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/67\">",
"      Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/68\">",
"      Yunis JJ, Mayer MG, Arnesen MA, et al. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/69\">",
"      Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 2009; 114:2273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/70\">",
"      Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin-ALK rearrangements: report of 6 cases. Blood 2003; 102:2568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/71\">",
"      De Paepe P, Baens M, van Krieken H, et al. ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 2003; 102:2638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/72\">",
"      Morris SW. ALK in NHL: To B (cell) or not to B (cell)? Characterization of the entity \"ALK+ DLBCL\" (editorial). Blood 2003; 102:2316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/73\">",
"      Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol 2009; 27:4211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/74\">",
"      Pasqualucci L, Dominguez-Sola D, Chiarenza A, et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011; 471:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/75\">",
"      Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/76\">",
"      Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A 2012; 109:3879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/77\">",
"      Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood 2011; 117:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/78\">",
"      Hummel M, Bentink S, Berger H, et al. A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 2006; 354:2419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/79\">",
"      Dave SS, Fu K, Wright GW, et al. Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 2006; 354:2431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/80\">",
"      Harris NL, Horning SJ. Burkitt's lymphoma--the message from microarrays. N Engl J Med 2006; 354:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/81\">",
"      Delabie J, Vandenberghe E, Kennes C, et al. Histiocyte-rich B-cell lymphoma. A distinct clinicopathologic entity possibly related to lymphocyte predominant Hodgkin's disease, paragranuloma subtype. Am J Surg Pathol 1992; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/82\">",
"      McBride JA, Rodriguez J, Luthra R, et al. T-cell-rich B large-cell lymphoma simulating lymphocyte-rich Hodgkin's disease. Am J Surg Pathol 1996; 20:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/83\">",
"      Boudov&aacute; L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102:3753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/84\">",
"      Abramson JS. T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management. Oncologist 2006; 11:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/85\">",
"      Achten R, Verhoef G, Vanuytsel L, De Wolf-Peeters C. T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. J Clin Oncol 2002; 20:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/86\">",
"      Bouabdallah R, Mounier N, Guettier C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003; 21:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/87\">",
"      Williams G, Foyle A, White D, et al. Intravascular T-cell lymphoma with bowel involvement: case report and literature review. Am J Hematol 2005; 78:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/88\">",
"      Colby TV. Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol 2012; 25 Suppl 1:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/89\">",
"      Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/90\">",
"      Castillo JJ, Beltran BE, Miranda RN, et al. Epstein-barr virus-positive diffuse large B-cell lymphoma of the elderly: what we know so far. Oncologist 2011; 16:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/91\">",
"      Dojcinov SD, Venkataraman G, Pittaluga S, et al. Age-related EBV-associated lymphoproliferative disorders in the Western population: a spectrum of reactive lymphoid hyperplasia and lymphoma. Blood 2011; 117:4726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?23/45/24282/abstract/92\">",
"      Adam P, Bonzheim I, Fend F, Quintanilla-Mart&iacute;nez L. Epstein-Barr virus-positive diffuse large B-cell lymphomas of the elderly. Adv Anat Pathol 2011; 18:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4703 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24282=[""].join("\n");
var outline_f23_45_24282=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1386915\">",
"      - Typical morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1386908\">",
"      - Plasmablastic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Alterations in BCL-6",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - (14;18) translocation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8316507\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8316514\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1202993\">",
"      Infectious mononucleosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17218494\">",
"      Gray zone lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17218451\">",
"      Anaplastic large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14074238\">",
"      Histologic transformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DISTINCTIVE CLINICOPATHOLOGIC SUBTYPES OF DLBCL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      T cell histiocyte rich large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Primary mediastinal large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Intravascular large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H763094\">",
"      Lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2612844\">",
"      EBV-positive DLBCL of the elderly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4703\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4703|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/49/31508\" title=\"figure 1\">",
"      Flow cytometry DLBCL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4703|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/45/34512\" title=\"picture 1\">",
"      Gastric B cell lymphoma CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/7/2165\" title=\"picture 2\">",
"      Diffuse large B cell NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/32/16903\" title=\"picture 3\">",
"      DLBCL path",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/43/25270\" title=\"picture 4\">",
"      DLBCL centroblast variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/57/37783\" title=\"picture 5\">",
"      DLBCL immunoblast variant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/39/42614\" title=\"picture 6\">",
"      DLBCL CD20 and T-cell membrane staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/29/7640\" title=\"picture 7\">",
"      DLBCL BCL-2 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/11/182\" title=\"picture 8\">",
"      DLBCL BCL-6 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/714\" title=\"picture 9\">",
"      DLBCL Ki-67 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/44/2761\" title=\"picture 10\">",
"      T rich large B cell NHL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/41/4757\" title=\"picture 11\">",
"      Intravascular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4703|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17452\" title=\"table 2\">",
"      Differential diagnosis of DLBCL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/32/17930?source=related_link\">",
"      Cardiac tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/47/25337?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of anaplastic large cell lymphoma, ALK positive",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4249?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9238?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of primary mediastinal large B-cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/46/25322?source=related_link\">",
"      Clinical manifestations, pathologic features, diagnosis, and prognosis of follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/32/8714?source=related_link\">",
"      Clinical presentation and diagnosis of primary gastrointestinal lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30217?source=related_link\">",
"      Clinical presentation, pathologic features, and diagnosis of primary central nervous system lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/18/31018?source=related_link\">",
"      Infectious mononucleosis in adults and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/12/18634?source=related_link\">",
"      Initial treatment of limited stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13511?source=related_link\">",
"      Intravascular large cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3609?source=related_link\">",
"      Pathobiology and treatment of Richter's transformation in chronic lymphocytic leukemia/small lymphocytic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5433?source=related_link\">",
"      Pathobiology and treatment of histologic transformation in the indolent non-Hodgkin lymphomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/27/38329?source=related_link\">",
"      Pathobiology of diffuse large B cell lymphoma and primary mediastinal large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/31/22009?source=related_link\">",
"      Pathologic characteristics of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/19/26930?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/60/27588?source=related_link\">",
"      Patient information: Diffuse large B-cell lymphoma in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26391?source=related_link\">",
"      Primary cutaneous large B cell lymphoma, leg type",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32599?source=related_link\">",
"      Primary lymphoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/20/41287?source=related_link\">",
"      Pulmonary lymphomatoid granulomatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/8/35974?source=related_link\">",
"      Thyroid lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26970?source=related_link\">",
"      Treatment and prognosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f23_45_24283="Autoantibodies in Addisons";
var content_f23_45_24283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79074&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Incidence of antiadrenal and other autoantibodies in patients with autoimmune adrenal insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tissue",
"       </td>",
"       <td class=\"subtitle1\">",
"        Incidence of antibodies, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adrenal",
"       </td>",
"       <td>",
"        60-70",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid peroxidase",
"       </td>",
"       <td>",
"        50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Parathyroid",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Islet cell",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Gonad",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ovary",
"       </td>",
"       <td class=\"sublist_other\">",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Testes",
"       </td>",
"       <td class=\"sublist_other\">",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Stomach",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Parietal cell",
"       </td>",
"       <td class=\"sublist_other\">",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Intrinsic factor",
"       </td>",
"       <td class=\"sublist_other\">",
"        9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24283=[""].join("\n");
var outline_f23_45_24283=null;
var title_f23_45_24284="ACC AHA Rx mechanical valve";
var content_f23_45_24284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Antithrombotic therapy in patients with mechanical heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that antithrombotic therapy is indicated in patients with mechanical heart valves in the following settings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Warfarin to achieve a goal INR of 2.0 to 3.0 after:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Aortic valve replacement (AVR) with bileaflet mechanical or Medtronic Hall valves if no risk factors* are present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Warfarin to achieve a goal INR of 2.5 to 3.5 after:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. AVR with bileaflet mechanical or Medtronic Hall valves if risk factors* are present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. AVR with Starr-Edwards or disc valves other than Medtronic Hall if no risk factors* are present.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Mitral valve replacement (MVR) with any mechanical valve.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull; Role of aspirin:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. After AVR or MVR in patients who cannot take warfarin, at a dose of 75 to 325 mg/day.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. At a dose of 75 to 100 mg/day in addition to warfarin in all patients with mechanical valves and in patients with biological valves who have risk factors*.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; In the first three months after AVR, warfarin to achieve a goal INR of 2.5 to 3.5.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following setting:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; In high-risk patients in whom aspirin cannot be used, clopidogrel (75 mg/day) or warfarin to attain a goal INR of 3.5 to 4.5.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk factors include atrial fibrillation, prior thromboembolism, left ventricular dysfunction, and a hypercoagulable state.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2008; 118:e523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24284=[""].join("\n");
var outline_f23_45_24284=null;
var title_f23_45_24285="Antibiotic doses for pneumococcal pneumonia in children";
var content_f23_45_24285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Doses of antimicrobials for the treatment of pneumococcal pneumonia in children older than three months",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Parenteral therapy",
"       </td>",
"       <td class=\"subtitle1\">",
"        Oral therapy (step-down therapy or mild infection)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"        susceptible to penicillin (MIC &le;2 mcg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Preferred regimens",
"       </td>",
"       <td>",
"        Ampicillin 150 to 200 mg/kg per day divided every 6 hours (maximum daily dose 6 g)",
"       </td>",
"       <td>",
"        Amoxicillin 90 mg/kg per day in 2 doses or 45 mg/kg per day in 3 doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Penicillin 200,000 to 250,000 units/kg per day divided every 4 or 6 hours (maximum daily dose 24 million units)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Alternative regimens",
"       </td>",
"       <td>",
"        Ceftriaxone* 50 to 100 mg/kg per day divided every 12 or 24 hours (maximum daily dose 4 g)",
"       </td>",
"       <td>",
"        Cefpodoxime 10 mg/kg per day divided in 2 doses (maximum daily dose 400 mg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefotaxime 150 mg/kg per day divided every 8 hours (maximum daily dose 10 g)",
"       </td>",
"       <td>",
"        Cefuroxime 20 to 30 mg/kg per day divided in 2 doses (maximum daily dose 2 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin 40 mg/kg per day divided every 6 or 8 hours (maximum daily dose 3.6 g)",
"       </td>",
"       <td>",
"        Cefprozil 15 to 30 mg/kg per day in 2 doses (maximum daily dose 1g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin 40 to 60 mg/kg per day divided every 6 or 8 hours (maximum daily dose 4 g)",
"       </td>",
"       <td>",
"        <p>",
"         Levofloxacin (if susceptible)",
"        </p>",
"        <p>",
"         Age 6 months to 5 years: 16 to 20 mg/kg per day divided in 2 doses (maximum daily dose 750 mg)",
"        </p>",
"        <p>",
"         Age 5 to 16 years: 8 to 10 mg/kg once daily (maximum daily dose 750 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid",
"        </p>",
"        <p>",
"         Age &lt;12 years: 30 mg/kg per day divided in 3 doses (maximum daily dose 1800 mg)",
"        </p>",
"        <p>",
"         Age &ge;12 years: 20 mg/kg per day divided in 2 doses (maximum daily dose 1200 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        <em>",
"         S. pneumoniae",
"        </em>",
"        resistant to penicillin (MIC &ge;4 mcg/mL)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Preferred regimens",
"       </td>",
"       <td>",
"        Ceftriaxone 100 mg/kg per day divided every 12 or 24 hours (maximum daily dose 4 g)",
"       </td>",
"       <td>",
"        <p>",
"         Levofloxacin (if susceptible)",
"        </p>",
"        <p>",
"         Age 6 months to 5 years: 16 to 20 mg/kg per day divided in 2 doses (maximum daily dose 750 mg)",
"        </p>",
"        <p>",
"         Age 5 to 16 years: 8 to 10 mg/kg once daily (maximum daily dose 750 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Linezolid",
"        </p>",
"        <p>",
"         Age &lt;12 years: 30 mg/kg per day divided in 3 doses (maximum daily dose 1800 mg)",
"        </p>",
"        <p>",
"         Age &ge;12 years: 20 mg/kg per day in 2 doses (maximum daily dose 1200 mg)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"5\">",
"        Alternative regimens",
"       </td>",
"       <td>",
"        Ampicillin 300 to 400 mg/kg per day divided every 6 hours (maximum daily dose 6 g)",
"       </td>",
"       <td>",
"        Clindamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        40 mg/kg per day divided in 2 doses (maximum daily dose 1.8 g)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Levofloxacin",
"        </p>",
"        <p>",
"         Age 6 months to 5 years: 16 to 20 mg/kg per day divided every 12 hours (maximum daily dose 750 mg)",
"        </p>",
"        <p>",
"         Age 5 to 16 years: 8 or 10 mg/kg once daily (maximum daily dose 750 mg)",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Linezolid",
"        </p>",
"        <p>",
"         Age &lt;12 years: 30 mg/kg per day divided every 8 hours (maximum daily dose 1800 mg)",
"        </p>",
"        <p>",
"         Age &ge;12 years: 20 mg/kg per day divided every 12 hours (maximum daily dose 1200 mg)",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clindamycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        40 mg/kg per day divided every 6 or 8 hours (maximum daily dose 3.6 g)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vancomycin 40 to 60 mg/kg per day divided every 6 or 8 hours (maximum daily dose 4 g)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Preferred for parenteral outpatient therapy.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Clindamycin resistance appears to be increasing in certain geographic areas among",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     infections.",
"    </div>",
"    <div class=\"reference\">",
"     From: Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis 2011; 53:e25, with permission of the Infectious Diseases Society of America. Copyright &copy; 2011 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24285=[""].join("\n");
var outline_f23_45_24285=null;
var title_f23_45_24286="Hypocretins in narcolepsy";
var content_f23_45_24286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75330&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Possible roles of orexins (hypocretins) in the pathology of narcolepsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 197px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of orexin signaling could cause cataplexy by reducing activity in the brainstem's motor excitatory systems or by providing less suppression of the motor inhibitory systems. Loss of orexin could cause sleepiness by reducing activity in the cholinergic and monoaminergic arousal systems or by reducing inhibition of sleep-promoting neurons in the rostral hypothalamus (preoptic area).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Siegel, JM. Cell 1999; 98:409.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24286=[""].join("\n");
var outline_f23_45_24286=null;
var title_f23_45_24287="Trunk lift PI";
var content_f23_45_24287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58290&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Trunk lift",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 152px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lie face down on a towel or blanket on the floor. Extend hands in front of the body. Lift the arms and upper body away from the floor. Hips should stay in contact with the floor. Hold for 3 to 5 seconds. Rest. Repeat 10 times.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f23_45_24287=[""].join("\n");
var outline_f23_45_24287=null;
